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Abstract 
Research that has examined the influence of depression symptoms and antidepressant 
medications on driving performance has revealed inconclusive findings (Brunnauer, Laux, 
Geiger, Soyka, & Moller, 2006; Bulmash et al., 2006; Ramaekers, 2003). The purpose of the 
present study was to elucidate the influence of depression symptoms and antidepressant 
medications on cognition and driving performances using self-report measures as well as an 
ecologically valid method measure, a driving simulator, and a clinical population. Two hundred 
and thirty-three drivers ranging in age from 18 to 35 years {M= 21.88; SD = 3.90 years) 
completed a screening measure that examined depressive and anxious symptoms, medication 
use, and self-reported driving behaviour on the Driving Behaviour Questionnaire (DBQ). Forty- 
three participants ranging in age from 18 to 35 {M= 24.24; SD = 5.05 years) also attended a 
laboratory session and completed a series of questionnaires designed to measure depression, 
driving habits, cognitive psychomotor functioning, and a diagnostic measure of MDD, two 
computerized tasks (one to measure attention and one to assess processing speed), and a 45 min 
simulated drive. In the overall sample, twenty-four (10.2%) participants were taking at least one 
antidepressant. Mean scores for depressive symptoms {M= 11.09; SD = 9.87) fell in the minimal 
range on the Beck Depression lnventory-11 (BDI-Il). A shortened version of the DBQ was 
created using this younger Canadian sample and correlation coefficients between the short and 
long version were excellent, ranging from .91 to .94. Overall, depressive symptoms and 
antidepressant use displayed little relationship to self-reported driving behaviour or driving 
performance on the driving simulator. However, our results do suggest that age (^ = .12) and the 
cognitive/affective (B = A2) impairments on the BDI-II are statistically significantly related to 
increased self-reported absent-minded driving behaviour {p = .03). Overall depressive symptoms 
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{B = -2.48) and cognitive/affective {B = 3.45) impairments were also related to inattention on a 
computerized task measuring attention {p < .05). The cognitive and affective impairments in 
depression were also positively related to visual perceptual ability {B = 2.02). The overall 
patterns of self-report data, neuropsychological data, and behavioural data suggest that although 
there is some consistency between self-report measures and neuropsychological data, this does 
not necessarily mean these impairments in attention translate into actual driving impairments on 
the simulator. Future studies could conduct a similar study using on-road performance as the 
behavioural measure of driving performance. 
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The Influence of Depression Symptoms and Antidepressant Medications on Cognition and 
Driving Performance 
Major Depressive Disorder (MDD) is a common mental disorder with both affective and 
cognitive impairments, including low mood, cognitive decline, and psychomotor retardation 
(Austin, Mitchell, & Goodwin, 2001; Hammar, Lund, & Hugdahl, 2003). Such impairments have 
the potential to interfere with an important daily function essential for functional autonomy, 
driving a vehicle (Brunnauer, Laux, & Zwick, 2009). Not only do mental disorders pose an 
increased risk for crashes because of the pathology itself (Brunnauer et al., 2009), but the 
pharmacological treatments that are prescribed to treat psychiatric disorders may also pose a 
threat to driving performance because of potential adverse side effects (Brunnauer, Laux, Geiger, 
Soyka, & Moller, 2006). Presently, there is a paucity of research on the influence of both MDD 
and antidepressant medications on driving performance. The little research that does exist reveals 
mixed results (Wingen, Ramaekers, & Schmitt, 2006). Therefore, it is essential to elucidate the 
influence of depression symptoms and antidepressant medications on driving performance. 
Major Depressive Disorder 
MDD is a common mental disorder that is delineated by affective, cognitive, and 
physiological symptoms. The Diagnostic and Statistical Manual of Mental Disorders, fifth 
edition (DSM-5; American Psychiatric Association [APA], 2013) uses a non-axial categorical 
classification that recognises a dimensional approach to diagnosing mental disorders. The 
characteristics of a Major Depressive Episode include both cognitive, affective, and 
physiological components, including five or more of the following symptoms over the same two- 
week period: depressed mood most of the day, anhedonia, significant weight loss or gain, 
insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy. 
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feelings of worthlessness or excessive guilt, inability to concentrate, and recurrent suicidal 
ideation (APA, 2000). The consequences of recurrent suicidal ideation can be dire as MDD is 
associated with high mortality, particularly for those who are male, single, live alone, or have 
prominent feelings of hopelessness (APA, 2013). In addition, at least one of these five symptoms 
must be either depressed mood or anhedonia. Finally, to meet diagnostic criteria, symptoms also 
have to cause significant impairment in functioning in social and/or occupational functioning. A 
MDD diagnosis is specified as mild (symptoms are distressing but manageable), moderate 
(intensity of symptoms are between mild and severe), and severe (intensity of symptoms is 
seriously distressing). Although symptoms can vary in severity, MDD is considered a severe 
psychiatric disorder (Ravnkilde et al., 2002). 
Major Depressive Disorder is a prevalent mood disorder and a debilitating disorder. The 
World Health Organization (WHO) reports that MDD will be the second cause of disability by 
2020 (Murray & Lopez, 1996). In terms of prevalence, those aged 18 to 29 have threefold higher 
rates of a diagnosis of MDD compared to those aged 60 and older (APA, 2013). Moreover, the 
APA reports that beginning in adolescence, females have 1.5 to 3-fold higher rates than males 
(APA, 2013). The APA also reports that the course for MDD is variable, ranging from 
individuals who do not experience symptoms for many years in between episodes to those who 
rarely experience remission. The risk of recurrence is higher in individuals who are young, 
experience a severe episode, and have had a previous episode (APA, 2013). 
Price, Mcleod, Gleich, and Hand (2006) found that prevalence rates were higher in 
younger populations including university students. These researchers examined the prevalence of 
MDD in a first-year Canadian university sample across disciplines using a diagnostic interview. 
They discovered that 14% of women and 7% of men met the criteria for MDD. In addition. 
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Eisenberg, Gollust, Golberstein, and Hefner (2007) used the Patient Health Questionnaire-9 
(PHQ-9) to assess depression and anxiety in undergraduate and graduate students. A depressive 
or anxiety disorder was found in 15.6% of undergraduates («= 1,181) and 13% of graduate 
students {n = 166). Tomoda, Mori, Kimura, Takahashi, and Kitamura (2000) investigated MDD 
prevalence using a structured interview in a first-year university Introductory Psychology sample 
in Japan. Ten percent of males and 28% of females met criteria for MDD. Some research also 
shows that depression is more prevalent across different ethnicities. Young, Fang, and Zisook 
(2010) found that Asian-Americans and Korean-American undergraduates across psychology, 
biology, and medicine programs had significantly higher levels of depression compared to 
Caucasian undergraduates as indicated by self-report scores on the PHQ-9. Therefore, MDD can 
be considered a highly prevalent mood disorder among university populations. 
Not only has research shown that MDD is a prevalent mood disorder, research also shows 
that MDD is highly comorbid with anxiety disorders such as Panic Disorder and Obsessive 
Compulsive Disorder (APA, 2013; Watson, 2005). Such comorbidity is considered a 
“...pervasive problem throughout the DSM” (Watson, 2005, p. 525). There is some contention in 
the literature surrounding anxiety syndromes and MDD being distinct clinical disorders 
(Gorman, 1996; Watson, 2005). Stulz and Crits-Christoph (2010) offer four possible 
explanations that may account for the comorbidity between MDD and anxiety disorders. Firstly, 
anxiety and depressive disorders could be distinct disorders with high comorbidity. Secondly, 
anxiety and depression could be distinct disorders but share symptoms of negative affect. 
Thirdly, anxiety and depression may be distinct disorders but the current measures of anxiety and 
depression do not demonstrate enough sensitivity to distinguish the constructs. Lastly, anxiety 
and depression may exist on a continuum. Furthermore, given that there is a great deal of overlap 
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between anxiety disorders and MDD, Watson (2005) argued that mood and anxiety disorders 
should be collapsed together into a class of emotional disorders. In addition, the Beck Depression 
Inventory - II and the Beck Anxiety Inventory were designed to discriminate between depression 
and anxiety. However, because of the comorbidity between these two constructs, these measures 
still overlap (r = .66; Beck, Steer, Ball, & Ranieri, 1996). Therefore, MDD and anxiety disorders 
are highly likely to co-occur and perhaps not always be distinct disorders. 
It is also well-documented in the literature that MDD is associated with impairment in 
cognitive functioning (Ravnkilde et al., 2002). Neuropsychological studies have examined 
cognitive functioning among individuals with MDD. The cognitive components of MDD can be 
objectively and reliably assessed using standardized tests (Brebion, Smith, & Widlocher, 1997). 
Therefore, neuropsychological studies have examined the cognitive components of MDD and 
discovered disturbances of executive functions (Fossati, Amar, Raoux, Ergis, & Allilaire, 1999; 
Hill, Keshawan, Thase, & Sweeny, 2004), attentional deficits (Egeland et al., 2003), dysfunction 
in psychomotor skills (Brebion et al.; Hill et al., 2004), and memory deficits (Fossati et al., 
1999). Researchers have found it difficult to ascertain to what extent these deficits are caused by 
true cognitive deficits or a lack of motivation in individuals with MDD (Ravnkilde et al., 2002). 
Executive dysfunction is proposed to be a consequence of MDD in young adults 
(Castaneda, Tuulio-Hennriksson, Morttunen, Suvisaari, & Ldnnqvist, 2008). Executive functions 
are the regulation of cognitive processes such as response inhibition, verbal fluency, nonverbal 
fluency, language comprehension, working memory, and planning (Kolb & Whishaw, 2009). For 
example, Egeland et al. (2003) compared individuals with MDD (w = 50) to controls {n = 50) on 
a measure of executive function, the Stoop Color Word Interference Test (SCWIT). Scores on 
the SCWIT are based on the number of seconds to name and read 48 coloured dots and words 
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that are not denoted by the name of the colour. Results revealed that individuals with MDD 
performed significantly worse across the SC WIT subtests including word (M= 19.42; SD = 
5.57), colour (M= 29.88; SD = 6.42), and colour-word (M= 53.54; SD = 13.45). In contrast, 
healthy controls were quicker to respond on the SCWIT subtests such as word (M= 16.54; SD = 
3.11), colour (M= 25.54; SD = 5.05), and colour-word (M =43.72; SD = 9.56). One potential 
limitation of this study was that most (n = 46) of the participants were taking psychotropic 
medications which makes it difficult to ascertain whether the depression or medications 
interfered with executive functions. However, further analyses revealed that there were no 
significant differences in test performance between individuals taking psychotropic medications 
and participants who were not taking medications. The implication is that MDD may interfere 
with executive functioning. 
Other evidence suggests that executive dysfunction among individuals with MDD is 
mixed and complicated by medication prescriptions. Fossati et al. (1999) compared individuals 
diagnosed with MDD (« = 20) upon admission to a hospital and healthy controls (n = 20). 
Individuals diagnosed with MDD were treated with antipsychotic medications. Participants with 
an MDD diagnosis performed more poorly on tests of executive function. For example, MDD 
participants produced significantly fewer words on the Verbal Fluency Semantic subtest 
(M = 26.15; SD = 7.6) compared to healthy controls (M= 35.2; SD = 8.8). In addition, 
participants with MDD performed significantly worse on the Wechsler Adult Intelligence Scale - 
III Digit Span Forward (M= 6.05; SD = 1.3) and Backward (M= 4.65; SD= 1.1) subtests 
compared to healthy controls (M= 7.35; SD = 1.2) and (M= 5.95; SD = 1.1), respectively. 
Participants with MDD also performed significantly worse on the Visuo-Spatial Backward 
subtest (M= 4.63; SD = 1.2) compared to controls (M= 6.43; SD = 1.0). Lastly, MDD 
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participants produced significantly fewer attempted card sorts (M= 17.25; SD = 3.7) and expected 
card sorts (M= 14.15; = 2.9) on the Delis Spontaneous Card Sorting Test compared to 
controls (M= 21.25; SD = 3.8) and (M= 16.85; SD = 2.8), respectively. However, participants 
with MDD did not show any deficits on the Wisconsin Card Sorting Task. Fossati and colleagues 
suggest that these findings are indicative of impairments in executive functions; namely, deficits 
in initiation ability, concept formation, and cognitive flexibility. One limitation of this study was 
that participants with MDD were using psychotropic medications. For example, when 
benzodiazepines were co-varied out of the analyses, differences in Verbal Span and the Visuo- 
Spatial subtests Span were no longer statistically significant suggesting that medications may be 
impairing executive functions rather than MDD itself. These findings suggest that executive 
dysfunction in individuals with MDD may be a consequence of medication. 
It is unclear if MDD, antidepressant medications, or both contribute to executive 
dysfunction in individuals with MDD. Hill et al. (2004) examined executive functioning in 
individuals with MDD with and without psychosis who had not taken antidepressant medications 
for more than six weeks on average. Hill et al. calculated a global executive function z-score 
which included the Wisconsin Card Sorting Test, the Stroop Color and Word Test, the Trail 
Making Test B, and the Controlled Oral Word Association Test to examine any impairment in 
executive functioning. Results revealed that compared to controls, individuals with psychotic 
{M= -0.75; = 1.18) and non-psychotic (M= -0.38; SD = 0.80) MDD performed significantly 
worse on measures of executive functioning compared to controls {M= -0.04; SD = 0.72). These 
findings suggest that executive dysfunction may be a consequence of MDD rather than 
medications. It is also possible that executive dysfunction is a consequence of psychoses. In 
contrast, Ravnkilde et al. (2002) examined 40 severely depressed inpatients and discovered no 
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dysfunctions in executive functioning compared to controls. However, a major limitation of this 
study was that most patients were medicated which again makes these findings difficult to 
interpret. Additional research would be useful to ascertain whether MDD itself and/or 
antidepressant medications are the cause of such dysfunction. 
Some researchers have also investigated whether executive dysfunction exists in 
individuals with MDD in remission. For example. Smith, Muir, and Blackwood (2006) 
discovered significant impairments on a measure of executive functioning, the Trail Making Test 
(TMT), in young adults {n = 42) whose MDD was in remission for at least one month compared 
to healthy controls {n = 30). The TMT assesses task switching and visual attention. These 
researchers reported that individuals whose MDD was in remission demonstrated differences on 
the TMT A (M= 29.6s; SD = 7.83s) and TMT B {M= 55.9s; SD = 15.13s) compared to controls 
who also completed the TMT A (M= 23.0s; SD = 4.83s) and TMT B {M= 45.3s; SD = 10.88s). 
However, the scores for both individuals whose MDD was in remission and controls all fell 
within the average range. Moreover, Wang et al. (2006) found no significant differences in 
verbal learning on the California Verbal Learning Test in individuals whose MDD was in 
remission (« = 42) compared to healthy controls (« = 46) and individuals who were currently 
depressed {n = 57). One explanation for these null findings may be that the participants with 
MDD were outpatients with mild to moderate symptoms (Castaneda et al., 2008; Wang et al., 
2006). Depressive severity may be related to executive dysfunction with greater impairment seen 
in more severe depressives (Castaneda et al., 2008). These studies suggest that results are also 
mixed for executive dysfunction in individuals whose MDD is in remission. 
Individuals with MDD often have difficulty with attention and difficulty focusing on 
several ongoing activities at one time (Ravnkilde et al., 2002). Egeland et al. (2003) found that 
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individuals diagnosed with MDD performed significantly worse as measured in milliseconds 
compared to controls on a measure of attention, the California Computerized Assessment 
Package (CalCAP). Egeland et al. (2003) calculated z-scores for the subtests of the CalCAP. 
Participants with MDD performed significantly worse on basal speed {M= 0.86; SD =1.10) and 
speeded attention (Af = 0.84; SD= 1.10) compared to controls {M= 0; SD = 0.72) and (M= 0; 
SD = 0.76), respectively. These scores were composite scores based on mean control derived 
z-scores. Participants with MDD did not perform significantly worse on the vigilance 
subtest (M= -0.23; SD = 1.14) compared to controls (M= 0; SD = 1). Therefore, evidence 
suggests that individuals with MDD are slow in speeded attention (Egeland et al., 2003). 
Furthermore, Mahurin et al. (2006) found that individuals with MDD performed slower on the 
TMT compared to controls. The TMT is used as both a measure of executive functioning and 
attention (Mitrushina, Boone, & D’Elia, 1999). Disturbances of attention appear to be a central 
problem for individuals with MDD. 
Slowed psychomotor speed is also considered a cardinal feature of MDD by the 
American Psychiatric Association (APA, 2000). Psychomotor speed can be assessed by 
examining reaction time, speech rate, and/or motor/mental speed (Taylor et al., 2006). Nelson 
and Chamey (1980) reported that up to 69% of individuals with MDD display symptoms of 
psychomotor retardation. Moreover, Brebion et al. (1997) found a significant negative 
relationship {r = -.46) between severity of psychomotor retardation and response bias on a verbal 
recognition memory test in 26 outpatients diagnosed with MDD. However, one limitation of this 
study was that 20 of the participants were taking a benzodiazepine, an antidepressant, or both, 
which may have influenced performance on this test. Taylor et al. (2006) also investigated 
psychomotor functioning in individuals who were depressed and using fluoxetine which is a 
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psychotropic medication that alleviates depression. Taylor et al. (2006) discovered that 
individuals who responded positively to fluoxetine verbalized significantly more words {M~ 
49.84; SD = 8.70) on the Controlled Oral Word Association Test compared to individuals who 
had no positive treatment response to fluoxetine (M= 38.75; SD = 4.88; Tj^=l .44). Therefore, 
psychomotor impairments may be more evident in individuals with depression who are 
unresponsive to certain psychotropic medications such as fluoxetine. Taylor et al. (2006) 
postulated that this may reflect a dopaminergic deficit in some individuals with depression. 
Therefore, some evidence suggests that psychomotor impairment is associated with MDD. 
Major Depressive Disorder (MDD) is associated with cognitive deficits and this may be 
consequence of motivational difficulties that are characteristic of MDD. To investigate the 
relationship between motivation and cognitive deficits, some researchers have investigated 
“response bias” which is considered a cognitive-behavioural paradigm of motivation (Austin et 
al., 2001) For example, Elliott, Sahakian, Herrod, Robbins and Paykel (1997) found that 
individuals with depression show a heightened response bias to negative feedback. Response 
bias was measured on the Delayed Matching to Sample Test and on the Tower of London Test. 
These tests require participants to solve problems while simultaneously giving participants 
feedback on whether or not a problem was solved correctly. Individuals with depression 
displayed a response bias on these measures. More specifically, individuals with depression 
solved more problems incorrectly (69 to 79% correct) after negative feedback compared to 
controls (90% correct). However, individuals with depression were taking antidepressant 
medications. Therefore, it is unclear whether motivational difficulties or antidepressant 
medications impact cognitive functioning. 
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Hartlage, Alloy, Vazquez, and Dykman (1993) have also proposed a “cognitive effort 
hypothesis” which suggests that the cognitive deficits that are associated with depression are 
contingent on the difficulty of the task that the depressed individual is performing. The more 
cognitive effort the task demands, the more cognitive dysfunction a depressed individual will 
experience. Thus, highly demanding tasks will have a detrimental impact on depressed 
individuals. Other factors have been proposed that may account for cognitive deficits in 
individuals with MDD including: desire to please, fatigue, psychomotor retardation, anxious 
inhibition, and monitoring of performance (Brebion et al., 1997). There are many uncontrolled 
variables, such as poor motivation, that may contribute to cognitive dysfunction in individuals 
with MDD. 
Antidepressant Medications 
Given that individuals with MDD experience both affective and cognitive deficits, it is 
crucial to consider effective treatments to help alleviate these symptoms. Research has 
demonstrated that non-pharmacological treatments are just as effective as pharmacological 
treatments for treating some forms depression. More specifically, cognitive-behavioural therapy 
(CBT), problem-solving therapy, and interpersonal therapy are effective treatments for 
depression (Gloaguen, Cottraux, Cucherat, & Blackburn, 1998; Mynors-Walis, Gath, Lloyd- 
Thomas, & Tomlinson, 1995). However, one serious drawback of these therapies is that they are 
difficult to access and expensive in the short-term (Boyce & Judd, 1999). The APA states in the 
Practice Guidelines for the Treatment of Patients with MDD that pharmacological treatments are 
an integral part of treatment, particularly for individuals who have moderate to severe symptoms 
(APA, 2000). 
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Psychotropic medications, are chemicals that alter mood and/or behaviour by acting on 
the central nervous system (Julien, 2004). Psychotropic medications are widely used to treat 
psychiatric disorders. In Canada, 7.2% of the general population is taking at least one type of 
psychotropic medication (Beck et al., 2005a). Psychotropic medications are considered a general 
group of medications some of which can include; benzodiazepines, antidepressants, mood 
stabilizers, antipsychotics, opiates, cholinesterase inhibitors, and anticholinergic medications 
(Goodwin & Jamison, 2007). Therefore, antidepressants are a subclass of psychotropic 
medications and include tricyclic antidepressants (TCAs), monoamine oxidase inhibitors 
(MAOIs), selective serotonin reuptake inhibitors (SSRIs), and selective norepinephrine reuptake 
inhibitors (SNRIs; Julien, 2004). Antidepressant medications are effective in treating depressive 
symptomatology (Dupuy, Ostacher, Huffman, Perils, & Nierenberg, 2011). However, 
antidepressant medications have been shown to induce many side effects including impairment 
in cognition, attention, and motor functioning (Ramaekers, 2003). 
First Generation Antidepressants. 
There are two classes of antidepressants that were introduced over 40 years ago: TCAs 
and MAOIs. The first TCA, imipramine, was accidently discovered by Swiss scientists who 
thought this drug would be effective in treating schizophrenia. However, it turned out that 
imipramine lifted depressive symptoms in individuals with MDD instead (Lopez-Munoz, 
Francisco, Alamo, & Cecilio, 2009). Around the same time that imipramine was discovered, 
MAOIs were also discovered to be effective in alleviating depressive symptoms. TCAs are 
considered effective because they block the presynaptic transporter protein receptors at many 
transmitter receptor sites including norepinephrine and serotonin (Julien, 2004). Therefore, first 
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generation antidepressants increase levels of monoamine transmitters such as norepinephrine and 
serotonin, which in turn alleviate depressive symptoms (Delgado, 2004; Julien, 2004). 
TCAs are considered the standard to which all other types of antidepressants are 
compared (Julien, 2004). The role of TCAs is to inhibit serotonin and noradrenaline reuptake 
which is important to achieve antidepressant effects (van den Broeck et al., 2009). In addition, 
TCAs also block postsynaptic histamine and acetylcholine receptors which can result in some 
adverse side effects including confusion, memory and cognitive impairments, blurred vision, and 
increased heart rate (Julien, 2004; Podweils & Lyketsos, 2002). In addition, impairment in motor 
skills has been documented (Oxman, 1996). Despite these side effects, evidence suggests that 
TCAs are effective at alleviating depression (Boyce & Judd, 1999). 
Tricyclic antidepressants have been shown to be clinically effective for depressed 
patients. Nelson et al. (1999) discovered that administration of the TCA nortriptyline to a sample 
of 81 depressed patients was associated with a 50% improvement on the Hamilton Depression 
Rating Scale. In addition, Furukawa, McGuire, and Barbui (2002) conducted a large meta- 
analysis examining the effectiveness of low-dose (75 and 1 OOmg/day) TCAs compared to 
placebo among individuals with depression. Furukawa et al. analyzed the findings of 35 studies 
and discovered that individuals taking a low-dose TCA of 75mg/day (OR = 1.65; 95% Cl [1.36, 
2.0]) and 1 OOmg/day (OR = 1.47; 95% Cl [1.12,1.94]) were at increased odds of experiencing 
less depressive symptoms within 8 weeks compared to placebo. Furukawa et al. conclude that 
treatment with a low-dose of TCAs for individuals with MDD is justified. 
MAOIs were first administered in the 1950s (Julien, 2004). There are two types of 
monoamine oxidase (MAO) enzymes that break down neurotransmitters such as norepinephrine, 
dopamine, and serotonin. The first type, MAO-A is located in serotonin and norepinephrine 
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terminals and inhibition of MAO-A creates an antidepressant effect. The second type, MAO-B, 
is found in dopamine neurons and inhibition of this enzyme induces side effects including 
significant cardiovascular side effects with interactions with certain foods such as cold 
medicines, cheeses, and wines (Julien, 2004). The side effects can be severe and cause 
orthostatic hypotension, hypertensive crises, and in some cases can be fatal (Lofufo-Neto, 
Trivedi, & Thase, 1999). However, in 2003, selegiline (Eldapril), a transdermal skin patch was 
put on the market, which avoided the dangerous food-drug interactions that occurred with oral 
administration. Compared to placebo {M= 21.26; SD = 9.37), selegiline has shown to 
significantly lower depressive symptoms in individuals with MDD (M= 18.67; SD = 9.41) after 
8 weeks of treatment (Amsterdam, 2003). These scores reflect symptoms on the Hamilton Rating 
Scale for Depression (HAM-D-28). A score above 20 suggests MDD. The only significant side 
effect that was reported was skin irritation (Amsterdam, 2003). MAOIs are used for treating 
anxiety, hypochondriasis, anorexia nervosa, bulimia, depressed episodes in bipolar disorder, 
dysthymia, depression in the elderly, and panic disorder (Julien, 2004). Although MAOIs have 
significant side-effects, these drugs are useful for treating MDD. Given the significant side 
effects of TCAs and MAOIs, in the late 1970s scientists sought to create drugs that would 
alleviate depressive symptoms without severe side-effects (Julien, 2004). Scientists were 
partially successful in their efforts; novel antidepressants were created. 
Second-Generation Antidepressants, 
One subclass of second-generation antidepressants is SSRIs, which are considered a first 
choice treatment for MDD (Anderson, 2000) and are also commonly used to treat anxiety 
disorders and MDD (Gorman, 2002; Ressler & Nemeroff, 2000). Serotonin is one 
neurotransmitter that is implicated in individuals with depression (Meyer & Quenzer, 2005). 
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Therefore, SSRIs help alleviate depression, at least in part, by inhibiting the reuptake of 
serotonin into the presynaptic cell. Serotonin is then available to bind with the postsynaptic 
receptor because it collects in the synaptic cleft. The six main SSRIs include: citalopram 
(Celexa), escitalopram (Lexapro), fluvoxamine (Luvox), paroxetine (Paxil), fluoxetine (Prozac), 
and sertraline (Zoloft) (Julien, 2004). In the United States between 1993 and 1995, SSRI 
prescriptions were on the rise (Donoghue et al., 1996). During this time, SSRI prescriptions 
increased by 133% compared to TCAs at 12% (Donoghue et al., 1996). In addition, in an Italian 
study, antidepressant consumption from 2006-2011 was found to have increased by 5% (Poluzzi 
et al., 2013). Atypical antidepressants such as SSRIs are commonly prescribed to treat depression 
and anxiety. 
The efficacy of SSRIs has been compared to TCAs. MacGillivary et al. (2003) conducted 
an in-depth meta-analysis and examined 11 studies using samples of individuals diagnosed with 
MDD from 10 different countries to investigate whether SSRIs were more efficacious than 
TCAs. Results revealed SSRIs were no more efficacious than TCAs. However, MacGillvary et 
al. (2003) also discovered that SSRIs are associated with lower dropout rates, or withdrawals 
from treatment, compared to TCAs. MacGillvary et al. (2003) postulated that this association 
may be related to the milder side effects of SSRIs compared to TCAs. For instance, Wilson and 
Mottram (2004) conducted a meta-analysis comparing the side effects of SSRIs and TCAs in 
older depressed patients. Results revealed an increased withdrawal rate for classical TCAs 
compared with SSRIs (RR= 1.30; Cl 95% [1.02, 1.64]). Common side effects of TCAs included 
dry mouth, drowsiness, dizziness, and lethargy. However, Wilson and Mottram reported some 
limitations of their study. First, there was a lack of standardization in reporting side effects 
among the studies examined. Second, participants were recruited from the community and 
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therefore these findings may not be generalizable to inpatient settings. Third, there may be a 
publication bias with studies that fail to find efficacy or tolerability for SSRIs compared to TCAs 
not being published. Despite these limitations, the literature suggests that SSRIs are considered 
effective for the treatment of depression and induce fewer side effects than TCAs. 
Although SSRIs have different side effects compared to TCAs, SSRIs do induce some 
side effects including: insomnia, anxiety, agitation, cognitive impairment, and sexual dysfunction 
(Julien, 2004; Targum, 2000; Wadsworth, Moss, Simpson, & Smith, 2005). Furthermore, 
hyponatremia, or low sodium concentration in the blood, is considered a potentially dangerous 
side effect of SSRIs (De Picker, Van Den Eede, Dumont, Mookens, & Sabbe, 2014). In addition, 
Julien (2004) describes three common side effects: serotonin syndrome, serotonin withdrawal 
syndrome, and SSRI-induced sexual dysfunction. Serotonin syndrome occurs when SSRIs are 
consumed with other drugs. In this case, individuals can experience disorientation, agitation or 
restlessness, changes in autonomic nervous system functioning, changes in neuromuscular 
functions, and visual hallucinations can occur. Serotonin withdrawal syndrome occurs in 60% of 
individuals who are long term users of SSRIs. Symptoms include: disequilibria, gastrointestinal 
upset, fatigue, lethargy, chills, and sensory and sleep disturbances. Lastly, SSRI-induced sexual 
dysfunction occurs in up to 80% of individuals with depression who are taking an SSRI. As the 
name suggests, symptoms can include problems with physiological arousal, orgasm, erection, 
and sexual interest (Julien, 2004; Michelson, Bancroft, Targum, Kim, & Tepner, 2000). 
Another class of second-generation antidepressants is Selective Norepinephrine Reuptake 
Inhibitors (SNRIs), which treat depression and anxiety by blocking the reuptake of 
norepinephrine and serotonin (Julien, 2004). For example, venlafaxine, an SNRI, is considered 
efficacious in reducing depressive symptoms. Davidson, Meoni, Haudiquet, Cantillon, and 
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Hackett (2002) reported that remission rates for venlafaxine were superior to placebo and to an 
SSRI, fluoxetine. More specifically Davidson and colleagues conducted a pooled analysis across 
5 randomized controlled trial studies which examined weekly remission rates up to 6 weeks in 
individuals diagnosed with Major Depression. Venlafaxine showed a statistically significant 
increase (p < .01) in remission rates of depressive symptoms compared to fluoxetine and placebo 
at weeks 3 and 6 for patients with severe anxiety symptoms at baseline. In contrast, for 
individuals taking fluoxetine, a statistically significant increase in remission rates was not seen 
until week 4. In addition, Baldwin (2006) concluded that three SNRIs, including venlafaxine, 
milnacipran, and duloxetine were efficacious in alleviating anxiety symptoms that often coincide 
with depression and certain anxiety disorders. Side effects associated with SNRIs include 
increased blood pressure and heart rate, sweating, and dry mouth. However, research suggests 
that one SNRI, reboxetine, is effective in improving attention and cognitive functioning in 
individuals with depression (Ferguson, Wesnes, & Schwartz, 2003). Therefore, SNRIs have 
more recently become another treatment choice for individuals with depressive and/or anxious 
symptoms. 
Antidepressant side effects can make complex tasks difficult for individuals taking 
antidepressant medications. One such complex task includes driving. For example, Brunnauer et 
al. (2006) conducted a naturalistic nonrandomized clinical study to investigate the effects of 
antidepressants on psychomotor function and potential driving ability. These researchers 
investigated visual perception, reaction time, selective attention, vigilance, and stress tolerance in 
100 inpatients who met the DSM-IV criteria for MDD and who were taking antidepressant 
medications. These domains were investigated because German guidelines propose that these 
components are critical for assessment of ability to drive in Germany. A failure is considered 
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scoring 1 standard deviation below the mean of normative data in any of these domains 
(Brunnauer et al., 2006). Results revealed that mild to moderate impairments in psychomotor 
functions that relate to driving an automobile were present in 60% of patients. Mild to moderate 
impairments were classified as failing in less than 40% of the test domains. Severe impairments 
were found in 16% of patients. Severe impairments were classified as failing in more than 40% 
of the test domains. In addition, patients using SSRIs displayed better test performance compared 
to those using TCAs. Twenty-eight percent of patients using SSRIs passed the tests without 
impairments compared to 10% of patients taking TCAs. However, patients who were taking a 
newer antidepressant, mirtazapine, displayed significantly better global driving ability scores in 
which 50% passed the tests without impairments. This suggests that mirtazapine may be 
associated with less severe deficits in psychomotor speed and integration of acoustic and visual 
stimuli. These results suggest that some antidepressants may interfere with driving performance. 
However, there is a paucity of research that has attempted to tease apart the effect of MDD and 
antidepressant medications on driving performance. 
More research examining the impact of medications on driving would be valuable 
considering that between 5% and 25% of drivers are taking psychotropic medications such as 
benzodiazepines (Kelly, Darke, & Ross, 2004). Furthermore, Beck et al. (2005a) examined The 
Canadian Community Health Survey: Mental Health and Well-Being (CCHS), a cross-sectional 
survey conducted by Statistics Canada between May and December 2002 which includes a 
sample of 36,984 Canadians aged 15 years and older, to look at prevalence rates for psychotropic 
medications in Canada. Among the general population, 7.2% of Canadians used psychotropic 
medications (Beck et al., 2005a). Usage was higher for women, the elderly, and SSRIs were the 
most commonly used. Beck et al. (2005b) examined antidepressant use in Canada using the 
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CCHS and discovered that 5.8% of Canadians used antidepressant medications. More 
specifically, among those diagnosed with MDD, over 40% reported using antidepressant 
medications. Given these prevalence rates and the potential impact that the side effects induced 
by medications can have on an individual, research examining the impact of antidepressant 
medications on driving ability is warranted. 
Antidepressant Medications and Driving 
Although medications can be beneficial to individuals with MDD and ultimately can 
improve their quality of life, antidepressant medications can also produce a range of side effects. 
Research suggests that side effects of psychotropic medications are well-documented (Barker, 
Greenwood, Jackson, & Crowe, 2004; Mishara & Goldberg, 2004). These side effects can 
include: sedation, lethargy, and impairment of human motor skills such as slower reaction times 
and reduced alertness (Ramaekers, 2003; Rapoport & Banina, 2007). Given that these side 
effects generally affect the central nervous system and thus human motor skills, it is likely that 
antidepressant medications influence driving ability. Operating a motor vehicle is a complex task 
that demands attention, alertness, and coordination (Tanida & Poeppel, 2006). Both experimental 
and epidemiological studies have documented the effects of alcohol on driving ability (Jones & 
Lacey, 2001; Moskowitz & Robinson, 1988). However, less attention has been paid to the 
impact of antidepressant medications on driving abilities (Brunnauer et al., 2006). 
Although there is a paucity of research dissociating the influence of antidepressant 
medications and MDD on driving performance, there are some epidemiological and experimental 
studies that have begun to explore this topic. Epidemiological and experimental studies have 
examined driving ability associated with antidepressant medications in the real world and using 
driving simulators or on-road tests, respectively (Rapoport et al., 2009). However, findings are 
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mixed and many of the studies have a number of limitations. For example, Brunnauer and Laux 
(2013) conducted a systematic literature review of second-generation antidepressants and driving 
performance and reported a lack of controlled patient studies. Moreover, there are no data to date 
examining some SSRIs such as agomelatine, duloxetine, bupropion, and viloxazine. 
Furthermore, Hetland and Carr (2014) conducted a literature review of study of psychotropic 
medications, including antidepressants, and driving from 1973 to 2013. These researchers 
examined the influence of second-generation antidepressants and driving performance and 
reported “inconsistency in the literature” (p. 500). In addition, Ravera, Ramaekers, de Jong-van 
den Berg, and de Gier (2012) conducted a literature review of epidemiological and experimental 
studies examining the influence of SSRIs on driving performance. Results suggest significant 
inconsistencies across the 15 studies that were selected. Ravera et al. suggest that future research 
is essential to uncover the relationship between MDD, antidepressant medications, and driving 
performance. 
Epidemiological studies 
Researchers have begun to investigate the relationship between MDD, antidepressant 
medications, and driving outcomes; the results have been mixed. Some evidence suggests that 
depression and/or antidepressants are associated with increased risk for a crash. For instance, 
Selzer, Rogers, and Kern (1968) found that 21% of drivers who were responsible for a fatal crash 
were considered clinically depressed. Furthermore, Ray, Fought, and Decker (1992) conducted a 
retrospective cohort study and discovered that elderly individuals who were taking TCAs were 
two times more at risk of being involved in a traffic collision compared to controls. In addition, 
Leveille et al. (1994) conducted a case-control study examining whether antidepressants and/or 
benzodiazepines were associated with risk of an injurious crash in older drivers. Results revealed 
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that antidepressants were associated with increased risk for injurious collisions among older 
adults (RR = 2.3, 95% Cl [1.1,4.8]). Moreover, Hu, Trumble, Foley, Eberhard, and Wallace 
(1998) conducted a panel data analysis on crash data from the Iowa 65+ Rural Health Study and 
found that use of antidepressants significantly increased risk of a crash in men (OR = 2.4, Cl not 
reported). Therefore, some evidence suggests that both MDD and antidepressant medications 
may impair driving performance. 
Comparing first and second-generation antidepressants side effects to driving 
impairments reveals contradictory results. For example, Walsh, de Gier, Christopherson, and 
Verstraete (2004) reported in a review paper that “Newer generation antidepressants do not seem 
to interfere with performance, except when used in higher doses” (p. 246). Furthermore, Walsh 
et al. (2004) conclude that first generation antidepressants may pose a risk to driving impairment 
but that new generation antidepressants are not a major problem for traffic safety. However, 
contrary to the conclusions of Walsh et al. (2004), Barbone et al. (1998) examined both 
pharmacy and police records to determine the association between antidepressant use and traffic 
crashes between 1992 to 1995 in the United Kingdom and found no increased risk of a traffic 
collision in a sample of adults taking TCAs; the OR was 0.93, 95% Cl [0.72, 1.21]. In addition, 
adults using SSRIs were not at increased odds of a traffic collision; OR was 0.85, 95% Cl [0.55, 
1.33]. Therefore, research findings on the influence of first and second generation 
antidepressants on driving performance appears mixed. 
More recent evidence also suggests mixed results for the influence of older and newer 
generation antidepressants on driving performance. Rapoport, Zagorski, Seitz, Hermann, Molam, 
and Redelmeier (2011) examined crash risk in adults aged 65 and older who were treated with 
antidepressants. Crash data was obtained from healthcare and transportation databases. Five 
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percent (n = 7, 393) of the total sample (N= 159,678) of older adults were taking an 
antidepressant medication one month prior to being involved in a crash. Results were calculated 
using hazard ratios (HR) and revealed that the greatest risk was the association between at fault 
crashes and antidepressants (adjusted HR = 1.09, 95% Cl [1.05, 1.12]). This finding contrasts 
Leveille et al. (1994) who did not find significant effects for drivers who were at-fault for a crash 
(n = 103), regardless if they were taking benzodiazepines or antidepressants. Paradoxically, 
Rapoport et al. also found that the risk of a crash for participants who were taking a first- 
generation antidepressant was not significant but there was a significant risk for participants 
taking second-generation antidepressants (adjusted HR = 1.10, 95% Cl [1.07, 1.13]). However, 
concurrently prescribed medications mediated the relationship between crashes and 
antidepressants. Participants who were taking an antidepressant and benzodiazepine (adjusted 
HR = 1.23, 95% Cl [1.17, 1.28]) displayed a significant increased risk of a crash. This risk, 
however, was no longer significant when a concomitant benzodiazepine was not taken (adjusted 
HR =1.01, 95% Cl [0.98, 1.04]). 
Similarly, Rapoport et al. (2008) conducted a case-crossover study examining 
psychotropic medications and crashes among individuals with dementia. Results revealed that 
first-generation antidepressants were associated with less risk (OR = 1.31, 95% Cl [1.07, 1.61]) 
than second-generation antidepressants (OR = 2.15, 95% Cl [1.78, 2.60]). Likewise, Ravera, van 
Rein, de Gier, and de Jong-van den Berg (2011) also found an increased risk of being in a crash 
with exposure to SSRIs, a second-generation antidepressant (OR = 2.03, 95% Cl [1.31, 3.14]). In 
addition, Gibson, Hubbard, Smith, Tatta, Britton, and Fogarty (2009) analyzed a primary care 
database in the United Kingdom to examine psychotropic medications and crash risk; short term 
(less than four weeks) use of SSRIs and use of first generation TCAs were not associated with a 
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significant risk of a crash. However, extended use of SSRIs increased risk (IRR =1.16, 99% Cl 
[1.06, 1.28]). 
Potential explanations for the findings that second generation antidepressants induce 
more driving impairment than first generation antidepressants include: rationale for prescribing 
the first-generation antidepressants (i.e., for insomnia rather than depression), more individuals 
who were prescribed first-generation antidepressants stopped driving because they were 
incapacitated, and/or the possibility that physicians prescribe newer antidepressants to frailer 
patients (Rapoport et al., 2011). These studies provide some evidence that suggests that second- 
generation antidepressants may be associated with more impairment in driving performance. The 
literature suggests that the connection between first and second generation antidepressant 
medications and driving impairment does not appear to be clear cut. Therefore, rigorous 
experimental designs are essential. 
Experimental studies 
Both driving simulators and on-road tests have been used for the purpose of exploring the 
influence of medications on driving performance. The published findings in this area are also 
mixed. The primary performance measures in simulated experiments and on-road tests include 
the Standard Deviation of Lateral Position (SDLP) and the Standard Deviation of Speed (SDS). 
SDLP refers to the degree of side-to-side movements of the car when it is in the correct lane and 
SDS is defined as speed variability (Verster, Volkerts, & Verbaten, 2002). 
Driving simulators. Driving simulators have been used as a tool to investigate 
psychotropic medications and driving performance. Driving simulators have some advantages 
over on-road tests as they can provide a safer method for evaluating driving performance, offer 
the opportunity for investigating risky road situations, and provide the opportunity for testing all 
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participants under the same conditions (Bedard, Parkkari, Weaver, Riendeau, & Dalhquist, 
2010). Moreover, Bedard et al. (2010) supported the validity and reproducibility of simulator 
driving evaluations with several findings; for instance, there is a moderate to strong (rs = .44 to 
.83) relationship between simulator performance and neuropsychological tests that predict 
crashes. Furthermore, there is a relationship between actual assessment of driving performance 
and number of errors recorded by a driving simulator (r = .74), suggesting that the simulator may 
be as accurate as a driving evaluator. Additionally, a different evaluator can reproduce the 
number of demerit points reported when using the play-back function of the driving simulator 
suggesting that a driving evaluator does not need to be present during the driving simulation 
further enhancing the ecological validity of driving simulators (ICC = .73-.87). In addition, 
evidence suggests that simulators are useful in predicting future crash risk. More specifically, 
Lee and Lee (2005) found that the frequency of the use of the indicator, or signalling to change 
lanes, is significantly inversely related to the incidence of traffic violations among individuals 
aged 60 and older, incidence rate ratio = 0.77, 95% Cl [0.62, 0.94]. Furthermore, Lee, Lee, 
Cameron, and Li-Tsang (2003) found that a driving simulator can identify inflated risk of a crash 
in older adults (OR =1.13, 95% Cl [ 1.00, 1.27]). Therefore, driving simulators can be 
considered a useful tool to assess driving performance. 
Many studies utilizing driving simulators have examined the impact of medications in 
healthy controls rather than clinical populations (see Rapoport & Banina, 2009; Sagberg, 2006). 
For example, Iwamoto et al. (2008) examined the impact of two antidepressants, 25 mg of 
amitriptyline and 10 mg of paroxetine on three driving tasks including SDLP, harsh braking, and 
car following in 17 healthy Japanese male participants. Iwamoto et al. discovered that acute 
doses of amitriptyline but not paroxetine significantly impaired SDLP and car following on the 
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driving simulator. More specifically, participants taking 25mg of amitriptyline had significantly 
more {M= 51.3; SD = 12.67) SDLP errors compared to those taking paroxetine {M= 38.9; SD = 
10.11). These researchers explained that these findings are not surprising as amitriptyline has 
antagonistic effects on the cholinergic, adrenergic, and histaminergic receptors. This can cause 
cognitive impairment, disruptions in balance, and sedation, respectively (Iwamoto et al., 2008). 
Some limitations of this study include use of healthy participants and acute dosing rather than 
long-term. 
Another study also investigated the impact of benzodiazepines on simulated driving 
performance in a clinical population. Partinen, Hirvonen, Dublin, Halavaara, and Hiltunen 
(2003) investigated the impact of 10 mg of zolpidem, 20 mg of temazepam, or placebo in 19 
women who were diagnosed with primary insomnia. Findings were akin to Staner et al. (2005); 
there were no significant differences in driving performance on a driving simulator between 
participants receiving zolpidem compared to placebo. Moreover, there were no significant 
differences between temazepam and placebo in driving performance. Partinen et al. reported that 
two explanations are possible for these null findings. Firstly, there were substantial individual 
differences in driving performance among the participants which may be responsible for the lack 
of differentiation between zolpidem and temazepam in this study. Secondly, participants may 
have been somewhat tolerant to zolpidem and temazepam as some participants may have 
previously used a benzodiazepine. Another limitation of this study is that the sample only 
included women. Thus, these findings may not generalize to men. The results of studies 
examining clinical populations such as participants with insomnia are valuable. However, 
examining a clinical population, such as participants with MDD, and antidepressant use would 
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help to elucidate the influence of antidepressants and MDD on driving performance (Rapoport & 
Banifta, 2007). 
The symptoms associated with depression may impair driving ability. Bulmash et al. 
(2006) used a driving simulator to investigate the driving ability of 18 outpatients who met the 
DSM-IV-TR criteria for MDD but were free of antidepressant medications and compared these 
participants to 29 control participants. Compared to controls, participants diagnosed with MDD 
displayed significantly slower reaction times (r|^ = 0.08) and increased crashes (r|^ = 0.10). More 
specifically, reaction time was slower for participants with MDD {M= 1.30 s; SE= 0.09 s) and 
number of crashes was higher (M= 3.83 s; SE = 0.87 s) compared to controls (M= 1.04 s; SE = 
0.07 s) and (M= 1.14 s; SE= 0.66 s), respectively. In addition, Brunnauer et al. (2008) 
conducted a pre-and-post study design and sampled participants who met DSM-IV-TR criteria 
for Major Depression and randomly assigned participants to receive a selective noradrenergic 
reuptake inhibitor (NARI), reboxetine (n = 20), and a noradrenergic and specific serotonergic 
antidepressant (NaSSA), mirtazapine (« = 20). Results suggest significant improvements in 
selective attention (p < .01), reactivity (p < .01), and a significant decrease in accidents on the 
driving simulator (p <.05). Given these findings, it would be reasonable to expect that depressed 
patients who are on antidepressant medications may have an improved driving performance. 
Shen et al. (2009) sampled 28 individuals who met the DSM-IV criteria for MDD and 
administered 30 mg of mirtazapine, a sedating antidepressant, for 30 days to half of participants. 
Participants completed a simulated drive on days 2, 9, 16, and 30. Just as Shen et al. (2009) 
hypothesized, participants who were given mirtazapine displayed greater driving safety as 
measured by an individual’s ability to adjust to lane position while driving. A score of 25 is 
considered the safest point in the lane. Lane position scores were significantly higher in the 
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untreated group (M= 30.2; SE = 7.4) compared to the treated group {M= 27.2; SE = 2.5) 
suggesting that the untreated group were less safe. Shen et al. (2009) provide several reasons for 
this finding, namely, a depressed mood may lead to decreased attention to the consequences of 
an accident, depressed individuals may have decreased concentration and cognitive functioning, 
and depressed individuals may have increased anxiety, irritability, sleep disturbances, fatigue 
which may all be detrimental to driving. 
In summary, the results of simulator studies reveal mixed findings for the effect of 
psychotropic medications on driving performance. While the results of studies using healthy 
participants suggest that some psychotropic medications impair driving ability, other research 
using depressed individuals suggests that antidepressants may actually improve performance. 
Therefore, simulator studies thus far have not established a consistent pattern and cogent 
explanation for the impact of psychotropic medications on driving. 
On-road driving tests. Experimental studies using on-road driving tests also have been 
utilized to investigate the impact of psychotropic medications on driving ability and psychomotor 
performance. Many of these studies utilize healthy volunteers to examine psychotropic 
medications and driving and have found mixed results. For example, Wingen, Bothmer, Danger, 
and Ramaekers (2005) examined the effect of two antidepressants, escitalopram and mirtazapine, 
on on-road driving performance. Wingen et al. conducted a 3-way crossover design study and 
administered the drugs in a 15-day series. Participants were administered 10 mg/day of 
escitalopram or 30 mg/day of mirtazapine in the evening on days 1 to 7 followed by 20 mg/day 
of escitalopram or 45 mg/day in the evening on days 8-15, or placebo. Participants engaged in an 
on-road test and psychomotor tests on the computer on days 2, 9, and 16 as these days were 
considered the acute period, dose increase, and a steady state, respectively. During the acute 
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period, participants in the mirtazapine group performed significantly worse on SDLP (M= 21.8 
cm; SE = 1.366 cm) compared to placebo (M= 17.9 cm; SE = 0.72 cm). Moreover, participants 
in the mirtazapine group displayed significantly more errors (M= 19.1; = 1.14) on a divided 
attention task compared to placebo (M= 17.0; SE = 0.96). A tracking error was considered to be 
the distance between the midpoint of the scale and the position of a cursor (measured in 
milometers). Mirtazapine did not impact performance during the dose increase or steady state 
phase. In addition, escitalopram did not impact driving or psychomotor performance in healthy 
volunteers. 
The findings of the Wingen et al. (2005) study are not that surprising considering that 
mirtazapine has been shown to have more sedative side effects than escitalopram (Aronson & 
Delgado, 2004; Kasper, Praschak-Rieder, Tauscher, & Wolf, 1997). However, Ramaekers et al. 
(2011) also found that a 1.5 mg of esmirtazepine did not significantly impact SDLP on an on- 
road test but a 4.5 mg dose of esmirtazapine produced a rise in SDLP that decreased following 
repeated doses. Therefore, studies utilizing healthy volunteers have revealed some mixed 
results. 
To obtain a better sense of the effect of antidepressant medications on driving, 
Ramaekers (2003) conducted a review of the major results of published randomized, double- 
blind studies from 1983 to 2000 examining the effects of antidepressants on on-road driving 
performance. They found 9 studies utilizing healthy participants and 1 study utilizing depressed 
participants. Results revealed that SDLP was significantly elevated compared to placebos and the 
effect was comparable to drivers with a blood alcohol concentration of 0.8 milligrams per 
millilitre. Ramaekers also suggested that using healthy volunteers possibly limits the clinical 
utility of the findings. 
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A limited amount of research has investigated on-road driving performance among 
individuals taking antidepressant medications. Wingen, Ramaekers, and Schmitt (2006) 
examined the effects of long-term antidepressant treatment on driving performance. Participants 
included 24 depressed patients who received a SSRI including citalopram, sertraline, paroxetine, 
or venlafaxine for 6-52 weeks and 24 healthy volunteers. All participants completed two 
standardized on-road driving tests and tests of cognition and attention in the laboratory. Results 
revealed significantly higher SDLP in depressed medicated participants 
{M= 20.5 cm; SE = 0.7 cm) compared to healthy controls (M= 18.0 cm; SE = 0.6 cm), 
suggesting poorer driving performance in depressed medicated participants. There were no 
significant differences between the different types of antidepressants and no significant group 
differences in the laboratory tests of cognition and attention and driving. Tests of cognition 
included: the visual verbal learning task, the change blindness task, the left-right test, the 
continuous performance test, the critical flicker fusion threshold, and the digit symbol 
substitution task. Wingen et al. concluded that depressive symptoms may have impacted driving 
performance rather than the SSRIs. Adding an additional group of depressed patients who are not 
taking antidepressant medications to this study would have best elucidated this question. 
There are many limitations in the current research examining the impact of medications 
on driving performance. Most studies utilised healthy volunteers. It can be argued that healthy 
participants may react differently to antidepressant medications compared to depressed patients 
and thus the findings of studies using healthy participants may not generalise to clinical 
populations (Ramaekers, 2003). In addition, few studies have investigated the effect of 
antidepressants using driving simulators and most studies have very small sample sizes 
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(Rapoport & Banina, 2007). Hence, more research is needed to tease apart the influence of 
antidepressant medications and depression on driving performance. 
Driving Behaviour 
Driver behaviour is a key factor in traffic collisions (Elander, West, French, 1993; 
Kontogiannis, Kossiavelou, & Marmaras, 2002). The Driving Behavior Questionnaire (DBQ; 
Reason, Manstead, Stradling, Baxter, & Campbell, 1990) was designed to measure conscious 
aberrant behaviours or human-made causes of traffic collisions. Reason et al. (1990) conducted a 
factor analysis {N = 520) on the DBQ and found three-factors that accounted for 33% of the 
variance collectively. These included errors (6.5%), violations (22.6%), and lapses (3.9%). 
Errors are related to perceptual, attention, and information processing errors. These often include 
misjudgements when driving (e.g., underestimating the speed of another vehicle; Lajunen & 
Summala, 2003). In contrast, violations reflect a driver’s style and driving habits, and have a 
motivational component (Ozkan, Lajunen, & Summala, 2006b; Reason et al.). Violations can 
include speeding, running a red light, or tailgating (Lajunen & Summala, 2003). Lapses are 
similar to errors and include difficulties with memory such as forgetting where the car is parked. 
The DBQ has been used in many different countries such as: Australia (Blockey & 
Hartley, 1995; Lawton, Parker, Manstead, & Stradling, 1997; Dobson et al., 1999), China (Xie & 
Parker, 2002), Denmark (Martinussen, Hakamies-Blomqvist, Moller, Ozkan, & Lajunen, 2013), 
Greece (Kontogiannis, Kossiavelou, & Marmaras, 2002), The Netherlands (Lajunen, Parker, & 
Summala, 1999), the United Kingdom (Parker et al., 1995; Lawton, Parker, & Stradling, 1997), 
United Arab Emirates (Bener, Ozkan, & Lajunen, 2008), United States of America (Owsley, 
McGwin, & McNeal, 2003), Spain (Gras et al., 2006), Sweden (Rimmo 2002), and Turkey 
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(Ozkan & Lajunen, 2005). However, to our knowledge, only one study has been published using 
a Canadian sample (see Cordazzo, Scialfa, Bubric, & Ross, 2014). 
Many versions of the DBQ exist and both the content and number of factors tend to vary 
across studies. In addition, some versions of the DBQ tend to be very long. DBQ versions have 
included 9-items (Martinussen, Lajunen, Moller, & Ozkan, 2013), 16-items (Lawton, et al., 
1997), 24-items (Parker et al., 2000), 36-items (Cordazzo, Scialfa, Bubric, & Ross, 2014), 50- 
items (Reason et al., 1990), 104-items (Aberg & Rimmd, 1998), and 112-items (Kontogiannis, 
Kossiavelou, & Marmaras, 2002). The number of items tend to vary as a result of country- 
specific variations (Ozkan , Lajunen, Chliaoutakis, Parker, & Summala, 2006a). 
Longer versions of the DBQ have displayed different factorial structures. Longer item 
questionnaires can also be considered overwhelming for participants and can jeopardize results 
as long questionnaires can lower completion rates (De Leeuw, Hox, & Dillman, 2008). 
Kontogiannis, Kossiavelou, and Marmaras (2002) distributed a 112-item version of the DBQ to 
individuals (« = 1,425) in 18 cities in Greece. Unfortunately, a response rate was not generated in 
this study. Results revealed a 7-factor solution, with five of the factors representing a distinction 
between errors and violation as in the original DBQ structure. Furthermore, Aberg and Rimmo 
(1998) added additional items that captured driver errors to the original DBQ. The new 104-item 
measure was completed by 1,400 drivers in Sweden, with a response rate of 69%. The original 
DBQ items confirmed the original three-factor solution. 
Shorter versions of the DBQ also apply different factorial structures and are validated 
across different countries. For example, Ozkan and Lajunen (2005) administered a Turkish 
translation of the original 50-item version DBQ with four additional items to measure aggressive 
violations to Turkish drivers aged 18 to 67 years. This version included a positive driver scale 
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and demonstrated a three-factor structure (violations, positive driver behaviours, and errors). In 
contrast, a 27-item version of the DBQ was administered cross-culturally to drivers in Britain, 
Finland, and The Netherlands and results supported a four-factor and two-factor solution 
(Lajunen, Parker, & Summala, 2004). Similarly, Cordazzo, Scialfa, Bubric, and Ross (2014)’s 
36-item version of the DBQ, which was adapted for North American drivers, supported a two- 
factor solution consisting of errors and violations but not lapses. Moreover, Parker, McDonald, 
Rabbitt, and Sutcliffe (2000) administered a 24-item version of the DBQ to elderly drivers (aged 
49 to 90 years) in England. This study had a good response rate (89%) and supported a five- 
factor solution that preserved the original DBQ three-factor solution. 
Although the DBQ has been extensively researched, few studies have examined the 
applicability of the DBQ across different age groups, particularly with younger drivers. The 
studies that have examined age groups have found mixed findings for the fit of the DBQ. One 
recent study conducted by Martinussen and colleagues (2013) investigated the original 50-item 
DBQ structure across seven age subgroups using both exploratory and confirmatory factor 
analyses in a Danish sample (N= 11,004). The results of the exploratory analyses supported a 
distinction between errors/lapses and violations, suggesting a distinction between unintentional 
and intentional aberrant driving behaviours. The EFA also supported a four-factor solution, 
which Martinussen et al. labelled confused errors/lapses, unfocused errors/lapses, emotional 
violations, and reckless violation/lapses. However, the exploratory analyses also revealed that the 
best fit was with the original DBQ structure, as well as the four-factor structure compared to the 
two-factor structure for the whole sample. Older drivers (ages 50-80 years) also showed a better 
fit (CFI = .859; 4-factor) than younger groups (ages 18-29 years; CFI = .804; 4-factor). 
Contradictory to these findings, Rimmo (2002) conducted a confirmatory factor analysis on data 
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from four different studies with four subsamples including new drivers {n = 2,248; aged 19 
years), inexperienced drivers {n =1,296; aged 21 years), young drivers {n =744; aged 22 to 27 
years), and experienced drivers (« = 976; aged 28 to 70 years). Results supported a four-factor 
solution and a better fit among new drivers {p < .05) compared to experienced drivers (p <.08). 
One explanation for these results may be that the age range for experienced drivers was broad 
which may lead to significant differences between the groups. Furthermore, Cordazzo et al. 
(2014) conducted a principal components analysis of the 36-item DBQ using an older sample 
from the Alberta Motor Association {N= 2,839; M= 60.65 years; SD = 13.81). Given that this 
sample did not include younger participants, Cordazzo et al. included a sample of University 
students {n = 456; M= 20.95 years; iSD = 2.16 years) in the analyses. However, Cordazzo et al. 
did not compare groups. The only reported finding pertaining to age was that age was negatively 
related to violations (fi = -0.40, p < .01). 
Given that driver behaviour can contribute to traffic collisions (Elander, West, French, 
1993) and that the DBQ measures driver behaviours, one application of the DBQ is to predict 
crashes. Parker, West, Stradling, and Manstead (1995) examined DBQ scores {N= 1,373) and 
crash record data, over a 6-year period (1987-1993), from the United Kingdom Driver and 
Vehicle Licensing Agency. Results revealed that high violation scores were associated with 
collisions including active loss-of-control collisions and passive right-of-way collisions. These 
researchers hypothesized that this may suggest that individuals who have high violation scores 
fail to adjust their speed to specific conditions (Parker et al., 1995). Furthermore, de Winter and 
Dodou (2010) conducted a meta-analysis of 70 studies and reported that DBQ errors (r = .10) 
and DBQ violations (r = . 13) were associated with self-reported crash involvement. In addition, 
there was a significant negative relationship between age and the violations-crash correlation 
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(standardized fi = -.48, p = .008) suggesting that younger drivers tend to have increased violation 
scores. Moreover, Cordazzo et al. (2014) found that violations significantly predicted self- 
reported collisions (fi = .25; p < .001). However, the r-squared value (R^ = .01) indicated that 
this predictor accounted for less than 1% of variance. 
Since the publication of the DBQ in 1990 by Reason et al., there has been extensive 
research on the structure of this instrument and the applicability of the DBQ across cultures. Less 
research has been conducted with the DBQ in young Canadian samples. 
The Present Study 
A principal feature of MDD is that it can induce cognitive and psychomotor disturbance 
including disturbances in executive functions, restlessness, attentional deficits, and slowed 
thought processes (APA, 2013; Brebion et al., 1997; Egeland et al., 2003; Hill et al., 2004). In 
addition, evidence suggests that individuals who are diagnosed with MDD often have 
motivational deficits (Ravnkilde et al., 2002). Both MDD and the antidepressant medications that 
are prescribed to treat MDD have the potential to cause cognitive and psychomotor disturbances. 
Antidepressant medications can impact the central nervous system causing deficits to 
psychomotor skills such as lethargy, slower reaction times, and reduced alertness (Ramaekers, 
2003; Rapoport & Banina, 2007). However, antidepressants may also improve cognition by 
lifting mood and improving attention and executive functions in the short term (Impey & 
Baldwin, 2013). Given the cognitive and psychomotor disturbances induced by both MDD and 
the antidepressant medications that are prescribed to treat MDD, it is important to consider how 
these disturbances might impact other areas of functioning. One such area is operating a motor 
vehicle. In 2009, there were 2,011 individuals fatally injured in a motor vehicle collision in 
Canada (Transport Canada, 201 la). While in 2008, approximately 38% of fatally injured drivers 
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in Canada tested positive for alcohol consumption (Transport Canada, 201 lb), no similar 
statistics are available for antidepressant medication use and vehicle collisions. Given that 
driving is a complex task that demands attention, alertness, and coordination (Tanida & Poeppel, 
2006) and that psychotropic medication use is prevalent in the general population, more research 
is needed to tease apart the effects of MDD and antidepressant medications on driving 
performance. 
To date, the literature on this topic is mixed. Both epidemiological and experimental 
studies report contradictory results with respect to the relationship between MDD, antidepressant 
medications, and driving performance (see Barbone et al., 1998; Leveille et al., 1994; Wingen et 
al., 2005). In addition, most of the current research has utilised healthy controls rather than 
clinical populations which limits the generalizability of these findings (Rapoport & Banina, 
2009). Therefore, the present study seeks to elucidate the influence of MDD and antidepressant 
medications on driving performances using an ecologically valid method, a driving simulator, 
and a clinical population. In addition, given that data using a Canadian sample to validate the 
DBQ is sparse, and that the factor structure of the DBQ has been inconsistent across younger age 
groups, our objective was to create a shorter version of the DBQ and to examine its psychometric 
properties in a younger Canadian sample. 
Hypotheses 
Given that the DBQ has only been validated on one Canadian sample and that the factor 
structure of the DBQ has been inconsistent across younger age groups, we aimed to explore the 
psychometric properties of a shorter version of the DBQ. We hypothesized that a shorter version 
of the DBQ would demonstrate good internal consistency and validity in a young adult Canadian 
sample. Furthermore, psychomotor disturbance is a cardinal feature of MDD (APA, 2000) and 
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research suggests that both MDD and antidepressant medications can interfere with attention and 
cognitive processing (Brebion et al., 1997; Ramaekers, 2003). Therefore, our secondary 
hypotheses were that participants who are taking antidepressant medications and/or are 
experiencing depressive symptoms would report more driving impairments on the DBQ and 
demonstrate deficits on measures of executive functioning (Trail Making Test [TMT]), visual 
perceptual ability (Motor-Free Visual Perception Test: Third edition [MVPT-3]), attention 
(Centre for Research on Safe Driving Attention Network Test [CRSD-ANT]), and visual 
information processing (Useful Field of View [UFOV]) compared to participants with fewer 
depressive symptoms. 
To restate, there were four main hypotheses: 
(1) We aimed to create a shortened version of the DBQ in a younger Canadian sample. We 
expected to observe good to excellent psychometric properties in this shorter version of 
the DBQ. Good to excellent psychometric properties are defined by Murphy and 
Davidshofer (2005) and Streiner (2003) to be Cronbach’s a of .80 as excellent and 
Cronbach’s a above .90 are considered redundant. 
(2) We expected to observe that higher levels of antidepressant medication use and/or 
depressive symptoms would be associated with higher levels of self-reported unsafe 
driving behaviour on the subtests of the shortened version of the DBQ. 
(3) We expected to observe that higher levels of antidepressant medication use and/or 
depressive symptoms would also be associated with higher impairments on measures of 
executive functioning (Trail Making Test [TMT]), visual perceptual ability (Motor-Free 
Visual Perception Test: Third edition [MVPT-3]), attention (Centre for Research on Safe 
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Driving Attention Network Test [CRSD-ANT]), and visual information processing 
(Useful Field of View [UFOV]). 
(4) We also expected to observe that higher levels of antidepressant medication use and/or 




Participants were recruited from undergraduate classes at Lakehead University and from 
members of the community. Recruitment methods used included newspaper advertisements, 
flyers. Thunder Bay television, speaking directly to undergraduate classes, and announcements in 
the Lakehead University Communications Bulletin. Participants who were enrolled in 
Introductory Psychology received up to five bonus points upon completion of the present study. 
Participants received one bonus point for completing the online screener, two bonus points for 
the laboratory portion, and two bonus points for the laboratory portion of this study. All other 
participants received a gift-card valued at $25 for each laboratory session ($50 total) for 
participation in this study. In addition, all participants were entered into a draw for a $100 gift- 
card for completing the online portion of this study. 
Inclusion criteria for this study included holding a valid General class (5) driver’s license 
and being between the ages of 18 and 65 (Bulmash et al., 2006). Based on a previous study using 
a clinical population with depression and a driving simulator, participants were excluded if they 
self-reported a serious head injury in the past, or psychotic disorder, or self-reported neurological 
or medical condition. In addition, participants were excluded if they were currently receiving 
treatment from a psychotherapist or counsellor for depression or anxiety. 
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A research assistant provided the investigator with a list of eligible participants from the 
online screening portion of this study who indicated that they were interested in participating in 
the laboratory sessions. Potential participants were contacted according to their preferred method 
of contact (email or phone). A laboratory appointment was scheduled, which required 
approximately 1.5 to 2.5 hours. Participants were instructed to bring their prescription 
medication bottles (if applicable) and visual-correcting glasses, if they required them, to the 
appointment. Research Ethics Board approval was obtained for this study and signed informed 
consent was also obtained from each participant. 
Materials 
Demographic questionnaire (Appendix A). A demographic questionnaire consisting of 
items pertaining to basic identifying information (e.g., age, ethnicity, sex) was administered to all 
participants. 
Driving Behaviour Questionnaire (DBQ; Reason, Manstead, Stradling, Baxter, & 
Campbell, 1990; Appendix B). The DBQ is a 50-item self-report measure of safe driving 
behaviours. Each item is scored on a 6-point Likert-type scale ranging from “0” {never) to “5” 
{nearly all the time). One item was excluded because it pertained to manual drivers only (i.e., 
''Attempt to drive away from traffic lights in third gear.’'). The original 50-item DBQ has been 
found to have three factors including errors (information processing errors), lapses (errors due to 
difficulties with memory), and violations (poor driving habits; Ozkan, Lajunen, & Summala, 
2006; Reason et al., 1990). The DBQ demonstrates good internal consistencies for errors, 
violations, and lapses (Cronbach’s a = .78, .79, and .64, respectively; Parker, Lajunen, & 
Stradling, 1998) In addition, Parker et al. (1995) found good test-retest reliabilities for errors (r = 
.69), violations (r = .81), and lapses (r = .75) over a 7-month interval. Ozkan, Lajunen, and 
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Summala (2006) conducted a longitudinal study to examine the test-retest reliability of the errors 
and violations subtests of the DBQ. Good test-retest correlations were reported after an interval 
of three years (n = 622) for errors {r = .50) and violations {r = .76). Furthermore, the DBQ 
demonstrates strong correlations with the Driving Behaviour Inventory, a measure of driving 
stress and performances (rs = .45 to .56; Westerman & Haigney, 2000). 
Driving history/habits questionnaire (Appendix C). This measure includes nine items 
that explore past driving information and is frequently used in research at the Centre for 
Research on Safe Driving. More specifically, this measure gathers information on number of 
kilometres driven in a week, number and time of any past collisions, and whether participants 
restrict their driving (e.g., daylight hours only). In addition, this measure gathers information on 
whether participants typically exceed the speed limit. 
Beck Depression Inventory-II (BDI-II; Beck, Steer, & Brown, 1996). The BDl-II is a 
21-item assessment instrument that examines the intensity of depression in adolescents and 
adults. Each item includes a list of four statements that reflect the severity of a symptom of 
depression. Higher scores are indicative of more intense depressive symptoms. Item scores are 
totalled for a total depression score, which can range from minimal (0-13), mild (14-19), 
moderate (20-28) to severe (29-63) (Beck et al., 1996). Whisman, Perez, and Ramel (2000) 
conducted a factor analysis and reported that the BDI-II is composed of a cognitive-affective 
factor and a somatic factor. The items that pertain to the cognitive-affective factor correspond to 
sadness, past failures, loss of pleasure, feelings of guilt, feelings of punishment, self-dislike, 
feelings of being critical of oneself, suicidal thoughts, crying, agitation, loss of interest, feelings 
of worthlessness, and irritability. In contrast, the somatic factor corresponds to items such as loss 
of energy, disrupted sleep, changes in appetite, difficulty with concentration, and fatigue. 
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BDI-II scores are strongly correlated (r = .83) with the Structured Clinical Interview for 
the Diagnostic and Statistical Manual for Axis I Mental Disorders (SCID-I) Major Depressive 
Disorder (MDD) scores in a university population suggesting that the BDI has excellent criterion 
validity (Sprinkle et al., 2002). Furthermore, a cut-off score of 16 corresponds to a sensitivity 
rating of 84% for detecting depressed mood. Sprinkle et al. (2002) also investigated the test- 
retest reliability of the BDI-II by administering this questionnaire to 46 university students (28 
women) at two time-points. The time interval between administrations was between 1 and 12 
days. Results showed that the BDI-II displays excellent (r = .96) test-retest reliability (Sprinkle et 
al., 2002). In addition, Dozois, Dobson, and Ahnberg (1998) conducted a psychometric 
evaluation of the BDI-II and reported that this measure as a whole has excellent internal 
consistency (a = .91). Therefore, the BDI-II can be considered a good instrument for measuring 
the severity of depression. 
Beck Anxiety Inventory (BAI; Beck & Steer, 1990). The BAI is a 21-item self-report 
measure of anxiety. Each item is rated on a 4-point Likert-type scale ranging from 0 (mt at all) 
to 3 {severely -I could barely stand it). Total scores from 0 to 9 are indicative of a normal level 
of anxiety; a score from 10 to 18 suggests mild to moderate anxiety; scores from 19 to 29 
indicate moderate to severe anxiety; and total scores between 30 and 63 reflect severe anxiety. 
The BAI has good internal consistency (Cronbach’s a = .92) and high test-retest reliability after 
1-week (r = .75; Beck, Epstein, Brown, & Steer, 1988). Furthermore, the BAI demonstrates 
good content validity {r = .85; Beck et al., 1988). Moreover, the BAI shows good concurrent 
validity with the Hamilton Anxiety Rating Scale - Revised (r = .51; Beck et al., 1988). The BAI 
and Beck Depression Inventory (BDI) demonstrate good discriminant validity; a moderate 
correlation between the BAI and BDI has been reported {r = .50; as cited in Beck & Steer, 1990). 
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However, Hewitt and Norton (1993) factor analysed the BAI and BDI after administering these 
measures to a heterogeneous clinical population and found that these two scales have good 
discriminant validity. The factor analyses revealed a two-factor solution in which the BDI loaded 
highest on factor 1 with loadings between .27 and .75. In contrast, BAI items loaded highest on 
factor 2 with loadings between .41 and .69. The BAI is considered a good measure of anxiety. 
Medication History Questionnaire (Appendix D). A follow-up questionnaire consisting 
of items pertaining to treatment was administered to all participants. In addition, all participants 
were asked if they have seen a therapist in the past or presently (e.g.. Are you currently seeing a 
therapist? Are you on any medications?). 
The Trail Making Test, A and B (TMT; Spreen & Strauss, 1991). The TMT is a paper 
and pencil task that asks participants to connect randomly distributed circles in a stated order. 
The TMT contains two components including TMT part A (TMT-A) wherein participants 
sequentially connect 25 numbers on paper and TMT part B (TMT-B) in which participants 
alternate between numbers and letters (e.g., 1, a, 2, b, 3, c). The TMT is scored based on the 
amount of time it takes the participant to complete the task. The TMT measures cognitive 
performance using measures of visual search, psychomotor speed, divided attention, cognitive 
flexibility, sequencing, and conceptual tracking (Mitrushina, Boone, & D’Elia, 1999). Research 
reveals that individuals with MDD perform significantly slower on the TMT compared to 
healthy controls (Mahurin, et al., 2006). Furthermore, Atkinson et al. (2010) have found good 
construct validity of three variants meaning that the TMT measures what it purports to measure. 
The Motor-Free Visual Perception Test: Third edition (MVPT-3; Colarusso & 
Hammill, 2003). The MVPT-3 is a paper and pencil test that measures visual perceptual ability 
independent of motor abilities and takes approximately 20 to 30 min to complete. More 
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specifically, this test measures perceptual processes such as spatial relationships, visual 
discrimination, figure-ground, visual closure, and visual memory (Colarusso & Hammill, 2003). 
The standard test scores range from 55 to 145 and have a mean of 100 and a standard deviation 
of 15. Cronbach’s alphas range from .69 to .90. The MVPT-3 was administered at two time- 
points with an interval of 34 days to 2,005 student participants from regular classrooms across 
the United States. Test-retest reliabilities were good (r = .S7-.92; Colarusso & Hammill, 2003). 
The MVPT-3 also has demonstrated good content and construct validity (Colarusso & Hammill, 
2003). 
The Useful Field of View® Test (UFOV®; Ball & Owsley, 1993; Edwards et al., 2005). 
The concept of useful field of view originated as a measure of visual acuity to diagnose eye 
disease which later progressed to a standard version of a computerized task to measure visual 
information processing and cognitive aging (Edwards et al., 2005). Today, the short version of 
the UFOV® is a computerized task that measures processing speed and attention. This task asks 
participants to complete three subtests including: processing speed, selective attention, and 
divided attention. The UFOV® short-form takes approximately 15 minutes to complete and the 
subtests increase in complexity as the test progresses and displays moderately high test-retest 
reliabilities. For example, Edwards et al. (2005) administered the UFOV® short-form to 66 older 
adults at two time-points, with an average interval of 10 days, and reported correlation 
coefficients of .68 to .88. Furthermore, Edwards et al. (2005) assessed the validity of the 
UFOV® short-form with the original UFOV®. Participants were 364 older adults who 
completed the standard version and short-version of the UFOV®. Results revealed a moderate 
correlation {r = 0.77) suggesting that the short-form of the UFOV® has validity. 
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Centre for Research on Safe Driving Attention Network Test (CRSD-ANT; Weaver, 
Bedard, & McAuliffe, 2011). The CRSD-ANT is a shorter version of the Attention Network Test 
(ANT). The ANT is a computerized reaction time test that combines a flanker task with arrows 
developed by Eriksen and Eriksen (1974) and a cued reaction time task created by Posner (1980). 
It takes approximately 20 min to complete and measures attention such as: alerting efficiency, 
orienting efficiency, and conflict efficiency. Alerting efficiency is considered a state in which an 
individual can achieve and maintain attentiveness. Orienting efficiency is defined as shifting 
attention from one location to the next while conflict efficiency, or executive function, is 
concerned with detecting and resolving any conflict in mental operations (Mahoney, Verghese, 
Goldin, Lipton, & Holtzer, 2010). MacLeod et al. (2010) collected data from 15 studies (« = 
1,129) to investigate the reliability of the ANT. This analysis resulted in low split-half 
reliabilities for the alerting and orientating indices, Spearman-Brown rs = .38 and .55, 
respectively. However, a moderately high Spearman-Brown correlation (r = .81) was discovered 
for conflict efficiency. The ANT has also demonstrated very good concurrent validity with the 
UFOV® in predicting simulated driving performance (Weaver, Bedard, McAuliffe, & Parkarri, 
2009). Therefore, the ANT is a useful tool for measuring attention. However, for researchers 
who are conducting driving research, the 20 minute version is too long. Therefore, Weaver, 
Bedard, and McAuliffe (2011) created a shorter 10 minute version called the CRSD-ANT. To 
create the shorter version, the neutral target condition of the original ANT was removed, the time 
intervals in the trial sequence were decreased, and the stimulus was changed from an arrow to a 
clip-art truck. The CRSD-ANT has 32 practice trials and 124 test trials. The test trials are in 
blocks of 64 and include a rest break in between blocks. The ordering of the trials is random. The 
CRSD-ANT demonstrates good agreement, or convergent validity, with the ANT (r = .92). 
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Wechsler Adult Intelligence Scale, Fourth Edition, Digit Span Subtest (WAIS-IV; 
Wechsler, 2008). The Digit Span subtest of the WAIS-IV is composed of a forward and 
backward digit strings task and a sequencing task. This subtest measures working memory, 
attention, and concentration (Wechsler, 2008) and was used as a measure of effort in the present 
study. Past research has used the Wechsler Adult Intelligence Scale - Revised (WAIS-R) and 
Wechsler Adult Intelligence Scale - third edition (WAIS-III) versions of the WAIS Digit Span 
subtest to assess effort among participants (Young, Sawyer, Roper, & Baughman, 2012). These 
versions differ from the WAIS-IV in that the earlier versions do not include a sequencing task. 
The Reliable Digit Span (RDS; Greiffenstein, Baker, & Gola, 1994) is a procedure that includes 
summing the longest string of digits that are repeated by the participant without error over both 
trials on the forward and backward conditions. RDS scores are used to assess suboptimal effort. 
Greiffenstein, Baker, and Goal (1994) used RDS scores with a cut-off score at <7 RDS to 
successfully distinguish individuals with persistent post-concussion syndrome from malingerers 
(specificity = .89; sensitivity = .68). Given that the WAIS-IV includes a sequencing task, the 
Reliable Digit Span-Revised (RDS-R) was developed to include this sequencing task (Young et 
al., 2012). The RDS-R is calculated by summing the digits repeated from the Sequencing trial to 
the RDS trial. Young, Sawyer, Roper, and Baughman (2012) conducted a retrospective review of 
the RDS and RDS-R in 277 patients in which 26% of patients had a diagnosis of a mood 
disorder. Results revealed that both the RDS and RDS-R displayed concurrent validity. The RDS 
(OR = 1.38, 95% Cl [1.20, 1.59]) and RDS-R (OR = 1.25, 95% Cl [1.13, 1.37]) differentiated 
groups on a pass/fail basis on the Word Memory Test. Last, this study found that RDS (cut-off = 
<7 and had a specificity of .81 and .92 and sensitivity of .49 and .24, respectively. The RDS- 
R (cut-off = <11 and <10) had a specificity of .78 and .89 and sensitivity of .48 and .32, 
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respectively. Although additional research needs to be conducted on the RDS-R, it can be 
considered a good measure of effort. 
Structured Clinical Interview for the Diagnostic and Statistical Manual-IV for Axis 
I Disorders Research Version, Non-Patient Edition (SCID-I-RV; First et al., 2002). The 
SCID-I-RV is a clinician-administered semi-structured interview that is composed of nine 
diagnostic modules that assess psychopathology (First et al., 2002). The SCID-I-RV has been 
considered the gold standard for assessing a valid self-reported diagnosis (Sanchez-Villegas et 
al., 2008). The Psychotic and Associated Symptoms module of the SCID-I-RV was administered 
to identify any participants who are experiencing a psychotic episode. The SCID-I-RV uses 
probe questions, follow-up questions, and skip-out questions to arrive at the correct diagnosis. 
Diagnoses are made during the interview and there is no scoring guide or algorithm (Sanchez- 
Villegas et al., 2008). 
The Manitoba Road Test (MRT; Appendix E). The MRT uses a road examination 
demerit-based scoring system to determine acceptable driving safety practices. This test was 
used to evaluate performance in the driving simulator task. Participants were given demerit 
points when they did not perform safe driving practices in five general categories including: 
starting/stopping, signal violations/right of way/inattention, moving on the roadway, 
passing/speed, and turning. Five or 10 demerit points were given for each infraction. More 
demerits were given for more serious mistakes (e.g., cutting off a vehicle) and fewer demerits for 
minor mistakes (e.g., drives at an uneven speed). A total of demerit points was calculated. The 
reliability and validity of this measure have not been assessed using driving simulators. 
However, the MRT has been used in previous research (see Weaver, Bedard, McAuliffe, 
Parkkari, 2009). 
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Driving Simulator. The STISIM DRIVE^”^ simulator (Systems Technology, Inc, 
Hawthorne, CA) has three networked computers that are connected to three 1T' monitors, a 
steering unit, and a foot pedal unit (see Figure 1). The steering unit includes a steering wheel, 
signal light, horn, speedometer, and odometer. The foot pedal unit includes both an accelerator 
and brake pedal. The researcher controls the simulator via a fourth computer. The simulator is 
designed to record input from the driver such as: speeding, lane excursions, collisions, and illegal 
turns. Using these measures, an overall index of driving performance can be calculated. Driving 
simulators are considered valid and safe for measuring driving performance (Bedard et al., 2010; 
Lee, Cameron, & Lee, 2003). 
Figure 1. Driving Simulator 
Patient Health Questionnaire, Ninth Edition (PHQ-9; Kroenke, Spitzer, & Williams, 
2001). The PHQ-9 was derived from the Patient Health Questionnaire (PHQ), which is a 3-page 
self-report measure that assesses 8 DSM-IV diagnoses (Kroenke, et al., 2001). The PHQ-9 is a 9- 
item inventory designed to screen for MDD. Each item is rated on a 4-point Likert-type scale 
that includes 0 {not at all), 1 {several days), 2 {more than half the days), and 3 {nearly every 
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day). A diagnosis of MDD is warranted if 5 or more of the 9 items occur on "'more than half the 
days'' and one of the items endorsed is either low mood or anhedonia. Item 9 which states: 
"Thoughts that you would he better off dead or hurting yourself in some way" counts if it is 
endorsed as a 1 or more. The PHQ-9 also includes a severity item which asks "How difficult have 
these problems made it for you to do your work, take care of things at home, or get along with 
other people? ” The severity item ranges from "not difficult at aW to "extremely difficult." In 
addition, scores range from 0 to 27; a score from 0 to 4 suggests minimal severity; scores from 5- 
9 indicate mild severity; scores between 10 and 14 suggest moderate severity; moderately severe 
scores range from 15 to 19; and total scores between 20 and 27 reflect severe MDD. Kroenke et 
al. (2001) conducted a reliability analysis of the PHQ-9 and found that the PHQ-9 demonstrated 
excellent internal consistency (Cronbach’s a = .89) in a primary care sample in = 3,000) and in a 
obstetrics-gynecology sample (Cronbach’s a = .86; w = 3, 000). Furthermore, the PHQ-9 
demonstrated high test-retest reliability after 48 hours (r = .84; Kroenke, et al., 2001). A PHQ-9 
score of >10 demonstrated a specificity and sensitivity of .88 and likelihood ratio of 7.1 
(Kroenke, et al., 2001). This measure also displays strong construct validity as it is highly 
correlated with the Medical Outcomes Study Short-Form General Health Survey (SF-20) mental 
health scale (r = .73). In addition, Titov, Dear, McMillan, Anderson, Zou, and Sunderland (2011) 
conducted a psychometric evaluation of the PHQ-9 and report adequate internal consistency 
(Cronbach’s a = .74; n = 172). Moreover, the PHQ-9 displayed convergent validity with the 
BDI-II (r = .72). The PHQ-9 is considered a good diagnostic tool for assessing MDD. 
Procedure 
A mass E-mail was sent out to students who were enrolled in the Introductory 
Psychology course at Lakehead University and undergraduate courses at Lakehead University. 
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The E-mail included a link to SurveyMonkey in which interested participants were directed to 
complete the screening questionnaire. The link was also available to members of the Thunder 
Bay community on Facebook. The first page of the SurveyMonkey webpage explained to 
participants that the initial online questionnaire would take up to 1 hour to complete and that 
participation was completely voluntary. Participants were then instructed to read the Information 
Letter A (see Appendix F), complete the Consent Form A (see Appendix G), and check a box 
online to indicate their consent to complete the online screening questionnaire. The screening 
questionnaire required participants to complete the demographics questionnaire (Appendix A), 
the DBQ (Reason et al., 1990; Appendix B), the driving habits and history questionnaire 
(Appendix C), the BDI-II (Beck et al., 1996), and the BAI (Beck & Steer, 1990) and the medical 
history questionnaire (Appendix D) which included items that gather information on medication 
use, previous treatments for depression, history of serious head injuries, and neurological 
conditions. After completion of the screening questionnaire, the next page of the online survey 
asked participants if they would be willing to be contacted via E-mail or phone to participate in a 
laboratory portion of the study. Next, participants were thanked for their participation. 
Subsequently, a research assistant scored the online screening questionnaire measures to 
determine eligibility for the laboratory portion of the study. Based on a previous study using a 
clinical population with depression and a driving simulator, participants were excluded if they 
self-reported a serious head injury in the past or psychotic disorder as measured using the 
psychotic screening module of the Structured Clinical Interview for the Diagnostic and Statistical 
Manual-IV for Axis 1 Disorders (SCID-I-RV; First, Gibbon, Spitzer, & Williams, 2002), or self- 
reported neurological or medical condition (Bulmash et al., 2006). In addition, participants were 
excluded if they were currently receiving treatment from a psychotherapist as seeking 
DEPRESSION, ANTIDEPRESSANTS, AND DRIVING 61 
psychotherapist could confound restuls. Inclusion criteria included holding a valid General class 
(5) driver’s license and being between the ages of 18 and 65 (Bulmash et al., 2006). Eligible 
participants who indicated that they would be willing to participate in the laboratory portion of 
this study were contacted by the researcher (Loretta Patterson) by their preferred method of 
contact (E-mail or phone). The researcher invited these eligible participants to attend two 
laboratory sessions. Eligible participants were scheduled for an appointment, which took 
approximately 1.5 to 2.5 hours to complete. 
Upon arrival to the Lakehead University Driving Laboratory (BB 1024), participants 
were instructed to read the Information Letter B (see Appendix H) and participants were asked if 
they had any questions about the study. After all questions had been answered, participants were 
asked to sign the Consent Form (see Appendix I). Next, participants completed the Trail Making 
Test (TMT; Spreen & Strauss, 1991) and the Motor Free Visual-Perception Test - 3 (MVPT-3; 
Colarusso & Hammill, 2003). Next, participants completed two computerized tests including a 
test of visual processing speed (UFOV; Ball & Owsley, 1993; Edwards et al., 2005) and a test of 
attention (CRSD-ANT; Weaver, Bedard, & McAuliffe, 2011). As a screening measure of low 
effort, the Digit Span subtest of the Wechsler Adult Intelligence Scale - Fourth Edition (WAIS- 
IV; Wechsler, 2008) was administered to participants in the laboratory. Last, the Psychotic and 
Associated Symptoms module of the Structured Clinical Interview for the Diagnostic and 
Statistical Manual-IV for Axis I Disorders Research Version, Patient Edition (SCID-I-RV; First 
et al., 2002) was administered to identify any participants who were experiencing a psychotic 
episode. 
Given that some individuals may experience simulator sickness, which is physical 
discomfort while using the driving simulator (Classen, Bewemitz, & Shechtman, 2011), 
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participants completed the driving simulation after the other neuropsychological tests. Our goal 
was to prevent any potential simulator sickness from interfering with any of the other laboratory 
measures. Participants were verbally instructed on how to use the simulator and completed a 10 
min practice session to help them adapt to the simulator. Next, participants completed a 40 min 
route that included both city and highway driving on the STISIM DRIVE^’^ simulator (Systems 
Technology, Inc, Hawthorne, CA). If participants experienced any physical discomfort due to the 
simulator, the drive was paused until the participant was ready to resume or the session was 
ended. The researcher was trained by another researcher at the Centre for Research on Safe 
Driving on specific Manitoba Road Test (MRT) scoring guidelines and scored the participants 
performance on the simulator using the MRT Demerit point system (Appendix E). Last, 
participants were asked to complete the Patient Health Questionnaire - 9 (PHQ-9; Kroenke, 
Robert, Spitzer, & Williams, 2001) to determine if participants met the DSM-IV-TR criteria for 
Major Depressive Disorder. Participants completed the PHQ-9 subsequent to the simulated drive 
to keep the experimenter blind to whether or not the participants met the diagnostic criteria for 
MDD. The participants also completed the medical history questionnaire (Appendix D) again. 
Last, participants were thanked for their participation and informed that they would be contacted 
in three months for a follow-up session in the laboratory. All participants were given a list of 
psychological services for psychological treatment (see Appendix J). Participants who met the 
diagnostic criteria for MDD were given a letter recommending they seek psychological treatment 
(see Appendix K). 
Participants were contacted three months following participation in the laboratory 
session. Each participant was invited to attend a second laboratory session to complete the 
measures a second time and in the same order. Participants who participated in the second 
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laboratory session completed the TMT (Spreen & Strauss, 1991), the MVPT-3 (Colarusso & 
Hammill, 2003), the UFOV (Ball & Owsley, 1993; Edwards et al., 2005) and the CRSD-ANT 
(Fan et al., 2002). The researcher then administered the Psychotic and associated symptoms 
module of the SCID-I-RV (First et al., 2002) to participants. Participants then completed the 
orientation drive and the 40 min driving route again. Last, participants completed the PHQ-9 
(Kroenke et al., 2001) and the medical history questionnaire (Appendix D). Participants were 
thanked for their participation and given a list of psychological services (see Appendix J). 
Participants who again met the diagnostic criteria for MDD were given a recommendation letter 
to seek psychological treatment (see Appendix K). All participants who were enrolled in 
psychology 1100 were awarded up to five bonus points towards their Introductory Psychology 
final grade for participation in this study. One point was awarded for the online screener, two 
points for the initial laboratory portion, and two points for the follow-up portion of this study. All 
other participants were awarded up to $50 in gift-cards for participation ($25 per lab session). 
Preliminary data screening. Data screening was performed to investigate missing 
values, accuracy of data entry, normality, and outliers. Accuracy checks on the data file were 
visually performed. Frequencies and descriptive statistics were run on the main variables to 
identify odd or extreme values. Histograms and scatterplots were also generated to identify 
atypical or abnormal distributions. Outliers were examined using the Cook’s distance statistic 
(D), which is a measure of the change in regression coefficients after deletion of a case. Cook’s 
distance assesses the overall influence of a case on a model. In the screener data, one case was 
visually identified on both the residual plots and histograms for factor 1 (D = 0.11) and factor 4 
(D = 0.07). This case was identified as the same female participant aged 19 years. Given that, 
Tabachnick and Fidell (2007) have suggested that Cook’s distance of greater than one may be 
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problematic and are suspect of being an outlier, this case was not considered problematic and 
was retained within the data set. No outliers were identified in the laboratory data. 
Statistical Analyses 
All analyses were performed with PASW Statistics version 21. To investigate hypothesis 
1, an exploratory factor analysis (using principal axis factoring for extraction and oblimin 
rotation) was generated on the longer version (49-item) DBQ (DBQ-LV) for the total sample. 
Cronbach’s alphas for the factors were also generated to investigate the internal consistency of 
the factors. Based on high factor loadings (greater than .300; Streiner, 1994) and the highest five 
item-total correlations per factor, a shortened version of the DBQ (DBQ-SV) was created. Next, 
a forced four-factor exploratory factor analysis (using principal axis factoring for extraction and 
oblimin rotation) was generated on the DBQ-SV in the younger Canadian sample. A forced-four 
factor EFA was used because factors 5 and 6 only contained 2 items each with factor loadings 
greater than .300. Cronbach’s alphas for the shortened version were also generated. Correlations 
between the DBQ-LV and DBQ-SV were also explored. 
To investigate hypothesis two, two standard multivariable regression models were used to 
examine the presence of possible relationships between age, sex, depressive symptoms, anxiety 
symptoms, and antidepressant use and self-reported unsafe driver behaviour. Participant age, sex, 
depressive symptoms, and anxiety symptoms were entered into Model 1. Model 2 included the 
variables listed in Model 1; however, the anxiety variable was removed as it is strongly 
correlated with depressive symptoms. In addition. Model 2 also included variables capturing the 
linear component of the age by cognitive/affective depressive variable interaction, age by 
somatic depressive variable interaction, and age by antidepressant use interaction. 
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To investigate hypotheses three and four, ordinary least squares regressions were run to 
investigate possible relationships between depressive symptoms and the CRSD-ANT response 
time, CRSD-ANT alerting score, CRSD-ANT orienting score, CRSD-ANT conflict score, TMT- 
A score, TMT-B score, MVPT-3 standard score, MVPT-3 errors, UFOV sum score, and UFOV 
divided attention score. The PHQ-9, BDI-II Cognitive/Affective score, BDI-II Somatic score 
were the predictor variables in these models. To investigate hypothesis four, an ordinary least 
squares regression was also run to investigate relationships between the PHQ-9, BDI-II 
Cognitive Affective, and BDI-II Somatic scores and the simulated drive (MRT score). 
Missing data. A formal analysis of missing values was completed for the online 
screening data and laboratory session data. For the online screening data, analyses revealed that, 
3.56% of the values and 14.55% of all cases of interest were incomplete. Eight participants were 
excluded because their missing values exceeded 10. Given that there the data were not 100% 
complete, a Missing Value Analysis (MVA) using the expectation-maximization (EM) algorithm 
was employed to correct for missing data (Graham, 2009). For the laboratory data, only one 
participant (female; age 21) had two missing data points on the BAI. This score was prorated for 
analyses. All other data were complete. 
The data were examined to investigate whether the assumptions of multiple regression 
were met. To examine multicoilinearity and singularity, a correlation matrix of all the predictor 
variables for the screener data and laboratory data was examined. With the expected exception 
of the BDI-II, BAI, and PHQ-9, there were no substantial bivariate correlations between 
predictors. These variables were expected to be significantly correlated as depression and anxiety 
symptoms are highly related (APA, 2013; Stulz & Crits-Christoph, 2010). Therefore, the 
assumptions were considered to be met. In addition, conditioning indices and variance 
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proportions (collinearity diagnostics) were also examined. Evidence that multicollinearity is 
suggested to exist if the condition index approaches 30 and the variance proportion is greater 
than .50 (Tabachnick & Fidell, 2007). Examination of collinearity diagnostics suggests that there 
is no evidence for multicollinearity and demonstrated that the assumption was met. To test the 
assumptions of normality, linearity, and homoscedasticity, histograms of the residuals and 
scatterplots of residuals against fitted values were examined. Visual inspection of the plots 
revealed that the data met the assumptions. 
Results 
Sample characteristics. 
Overall, a total of 275 participants completed the online screener. Only participants 
ranging in age from 18 to 35 years were included in the analyses (« = 236). However, one 
individual was excluded due to missing data across several measures resulting in a final sample 
size of 235. The average age of participants was 21.84 years (SD = 3.90 years); the majority of 
participants were women (79.1%). Four participants did not specify their age and were excluded 
from analyses. Participants’ characteristics are presented in Table 1. Descriptive statistics for the 
main variables of interest are displayed in Tables 2 to 6. Intercorrelations among all online 
screener variables are displayed in Table 7. 
Overall, a total of 124 participants agreed to be contacted for further participation. These 
participants were invited to complete the laboratory portion of this study. Forty-three participants 
participated in the laboratory session. Two participants were considered ineligible; one due to a 
having a neurological disorder and the other began seeing a therapist at the time of participation. 
The average age of participants was 24.24 years (SD = 5.05 years) and the majority were women 
(81.4%; n = 35). Only 2 participants reported taking an antidepressant medication; both were 
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taking an SSRI. No participant was psychotic. All participants scored in the minimal range on 
the BDI-II except one participant who scored in the moderate range. Descriptive statistics and 
intercorrelations for the main variables of interest are displayed in Tables 8 to 12. 
The WAIS-IV digit span subtest was administered as a measure of effort. Reliable digit 
span (RDS) was originally used with the WAIS - Revised and WAIS - III. RDS is calculated by 
summing the longest digit forward score and the longest digit backward score. Reliable digit 
span - revised (RDS-R) can be calculated for the WAIS-IV as it sums the digits repeated from 
the longest digit sequencing trial to the RDS trial. Young, Sawyer, Roper, and Baughman (2012) 
report that an RDS cut-off = <6 (sensitivity = .24; specificity = .92) and an RDS-R cut-off = <10 
(sensitivity = .32; specificity = .89) are recommended to achieve acceptable specificity. Both 
RDS and RDS-R were calculated. One female participant scored an RDS of 7. This same 
participant scored higher than the RDS-R cut-off and was therefore included in analyses. All 
other participants also scored 11 or greater on the RDS-R suggesting that these participants met 
the cut-off for putting in full effort. Only twelve of the 43 participants, who completed the 
laboratory portion of this study, completed the 3-month follow-up. Analyses were not conducted 
on these 12 participants, as the sample size was too small. 
Main Hypotheses 
Hypothesis 1. We aimed to create a shortened version of the DBQ in a younger Canadian 
sample. We expected to observe good psychometric properties in this shorter version of the 
DBQ. An exploratory factor analysis (EFA) analysis (using principal axis factoring for 
extraction and oblimin rotation) was conducted on the original 49 items of the DBQ. After 
excluding participants with greater than 10 variables missing, an EFA was conducted for the 
remaining 233 participants. Streiner (1994) argues that, when conducting an EFA, “there should 
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Table 1 






Approximately how many kilometers (miles) do you drive per week? {n = 234) No. (%) 
0-20km (0-12 miles) 44 (18.7) 
21-50km (13-31 miles) 74 (31.5) 
51-lOOkm (32-62 miles) 73 (31.1) 
Over 100 km (over 62 miles) 43 (18.3) 
When driving, how many accidents (involving a person, car, or fixed object) 
have you been involved in? {n = 225) 
# At fault 
Range 0-5 
Mean(SD) 1.4 (0.8) 
# Not at fault 
Range 0-3 
Mean(SD) 1.4 (0.6) 
How long ago was your last at fault car accident involving a person, car, or 
fixed object? {n = 233) No. (%) 
Less than 1 year 26 (11.0) 
1- 2 years 19(8.1) 
2- 3 years 8(3.4) 
3- 4 years 4(1.7) 
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4- 5years 6 (2.5) 
5- 10 years 8 (3.4) 
More than 10 years 3(1.3) 
Never had an accident 159 (67.4) 
How long ago was your last not at fault car accident involving a person, car, or 
fixed object? (« = 232) No. (%) 
Less than 1 year 20 (8.5) 
1- 2 years 17 (7.2) 
2- 3 years 9(3.8) 
3- 4 years 6 (2.5) 
4- 5 years 5 (2.1) 
5- 10years 7 (3.0) 
More than 10 years 2 (0.8) 
Never had an accident 166 (69.9) 
DHQ = Driving Habits/History Questionnaire; Km = kilometers 
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Table 2 
Descriptive statistics for the DHQ: Purposes for driving in a week 
Items No. (%) M (SD) # of 
times per week 
For what purposes do you drive in a typical week? 
Groceries 148 (62.7) 1.7 (0.9) 
Attending health-related appointments 80(33.9) 1.3 (0.8) 
Attending social events 186 (78.8) 3.0 (2.1) 
Worship 23(9.7) 1.6 (0.8) 
Hobbies 126(53.4) 3.8 (2.5) 
Work/school 191 (80.9) 5.9 (2.7) 
Family events 108 (45.8) 1.6(1.0) 
Other 57(24.2) 2.8 (1.9) 
DHQ = Driving Habits/History Questionnaire; M= Mean; SD = Standard Deviation; N = 235 
DEPRESSION, ANTIDEPRESSANTS, AND DRIVING 71 
Table 3 
Descriptive statistics for the DHQ: Stressful driving situations, restricting driving, and speed 
Items 
Which driving situation(s) do you find stressful, uncomfortable, or avoid No. (%) 
when possible?  
Turning left at intersections 34(14.4) 
Navigating parking lots 37(15.7) 
Driving at night 77 (32.6) 
Changing lanes 14 (5.9) 
Backing up 63 (26.7) 
Maintaining the speed limit 17 (7.2) 
Parallel parking 144 (61.0) 
Driving in bad weather 166 (70.3) 
Driving in unfamiliar areas 120 (50.8) 
Driving in heavy traffic 117 (49.6) 
Driving with passengers in the car 20 (8.5) 
Other 19(8.1) 
Driving alone 10(4.2) 
None of the above 19(8.1) 
Some people restrict their driving to certain situations. Do you restrict your 
driving to: 
Daytime 17 (7.3) 
When accompanied by a passenger 1 (3.0) 
Outside of rush hour 16 (6.9) 
Local routes 19(8.2) 
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Fair weather 40 (17.2) 
None of the above 159 (68.2) 
Other 224 (96.1) 
What speed do you typically drive on local streets? 
35 km/hr or less 3 (1.3) 
36-45 km/hr 7 (3.0) 
46-55 km/hr 99(42.1) 
56-65 km/hr 114 (48.5) 
66 km/hr or more 12 (5.1) 
What speed do you typically drive on major highways? 
85 km/hr or less 3 (1.3) 
86-95 km/hr 32(13.6) 
96-105 km/hr 132(56.2) 
106-115 km/hr 63(26.8) 
116 km/hr or more 5 (2.1) 
DHQ = Driving Habits/History Questionnaire; N = 235 
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Table 4 















(« = 45) 
Women 
(«= 186) 






11.09(9.87) 0-59.85 11.18(12.01) 0-48.63 11.10(9.33) 
7.62 (7.33) 0-45 7.98 (9.20) 0-33 7.56 (6.82) 
2.61 (2.36) 0-12 2.50(2.59) 0-13 2.63 (2.31) 
10.34(9.71) 0-42 8.96(10.42) 0-60 10.73(9.52) 
No. (%) Range No. (%) Range No. (%). 
0-19.95 201 (85.53) 0-19.95 39(86.67) 0-19.95 158(84.95) 
21-27.30 20(8.51) 25.20- 1 (2.22) 21-27.30 18(9.68) 
25.20 
29.40-59.85 14(5.96) 32.55- 5 (11.11) 29.40- 10(5.38) 
59.85 48.63 
Note. BDI-II Total = Beck Depression Inventory - II; BDI-II C/A = Beck Depression Inventory 
- II Cognitive/Affective; BDI-II S = Beck Depression Inventory - II Somatic; BAI = Beck 
Anxiety Inventory; SD = Standard Deviation; ^ Four participants did not specify their sex; ^ The 
BDI-II total excluded one item (suicide item) and scores were prorated to adjust for this. 
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Table 5 
Descriptive statistics for medication use by total sample and sex 

























































Note. SSRI = Selective Serotonin Reuptake Inhibitor; SNRI = Selective Norepinephrine 
Reuptake Inhibitor; TCA = Tricyclic Antidepressant; "Four participants did not specify their sex. 
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Table 6 









(« = 45 ) 
Women 
(«= 186) 
Range Mean (SD) Range Mean (SD) Range Mean (SD) 
0-66 16.28(10.45) 0-43 15.69(11.35) 0-66 16.32(10.16) 
0-53 15.80(8.67) 0-40 14.23(9.39) 0-53 16.07(8.33) 
0-50 13.41 (9.94) 0-38 12.80(10.86) 0-50 13.44(9.73) 
0-50 8.33 (6.61) 0-28 7.57(6.94) 0-50 8.55(6.58) 
Note. DBQ-LV = Driver Behaviour Questionnaire - Long Version; SD = Standard Deviation; 
® Four participants did not specify their sex. 
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Table 7 
Intercorrelotions among all screener variables 
Variables 1 
1. Age 
2. Sex ^ 















.28** .16* .21** 
Note. BDI-II C/A = Beck Depression Inventory - II Cognitive Affective component; BDI-II S= 
Beck Depression Inventory - II Somatic component; BAI = Beck Anxiety Inventory; AntiDEP = 
Anti-depressant medications. 
“AT = 235. '’N= 231. 'Af = 225. “Ar= 234.'AT= 225. ‘AT= 235. 
*p <.05. *♦ p <.01 
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Table 8 


















Range Mean (SD) 
50.10- 87.49 
160.40 (27.94) 
16.70- 23.40 17.01 
(1.22) 
16.70- 60.00 20.03 
(9.08) 




16.70- 3.40 17.54 
(2.37) 
16.70- 0.10 18.38 
(4.74) 















Note. UFOV = Useful Field of View; SD = Standard Deviation; UFOV-1 = Processing Speed; 
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Table 10 











(« = 8) 
Women 
{n = 35) 
Range Mean (SD) Range Mean (SD) Range Mean (SD) 
0-22.05 7.59(5.99) 2.10-19.95 7.74(7.36) 
0-14 4.37(6.86) 1-12 5.13(4.22) 
0-11 2.86(2.63) 0-8 2.25(3.06) 
0-25 7.67 (7.36) 0-23 7.50 (9.37) 
0-20 4.16(4.06) 0-20 5.63(6.59) 
0-22.05 7.56 (5.76) 
0-14 4.20(3.68) 
0-11 3.00(2.56) 
0-25 7.70 (6.99) 
0-14 3.83 (3.29) 
Note. BDI-II C/A = Beck Depression Inventory - II Cognitive/Affective; BDI-II S = Beck 
Depression Inventory - II Somatic ; BAI = Beck Anxiety Inventory; SD = Standard Deviation; 
PHQ-9 = Patient Health Questionnaire - 9. 
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Table 11 
Descriptive statistics for MRT, TMT, MVPT, and WAIS-IV for laboratory sample by total 














(« = 8) 
Women 
(« = 35) 
Range Mean (SD) Range Mean (SD) Range Mean (SD) 
15-170 80.23 (33.31) 
11-69 23.72(11.19) 
18-175 54.95 (27.40) 
I- 19 9.58(4.98) 
73-143 98.70(18.18) 
7-17 12.00(1.99) 
II- 23 17.26(2.47) 
30-170 78.75 (41.73) 
11-30 21.50(6.07) 
24-83 49.00 (20.40) 
15-160 80.57(31.80) 
13-69 24.23 (12.07) 
18-175 56.31 (28.84) 
1-18 8.13 (6.66) 1-19 9.91 (4.57) 
76-137 106.88(22.64) 73-143 96.83(16.84) 
10-16 12.13 (1.89) 7-17 11.97(2.04) 
15-21 17.25(2.12) 11-23 17.26(2.57) 
Note. MRT = Manitoba Road Test; TMT = Trail Making Test; MVPT = Motor Free Visual 
Perception Test-4; ^scored in seconds; RDS = Reliable Digit Span; RDS-R = Reliable Digit 
Span - Revised 
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Table 12 
Intercorrelations among all laboratory predictor variables 
Variables 1 2 3 
1. BDI-II C/A 
2. BDI-II S .59** 
3. PHQ-9 .62** .47** 
Note. BDI-II C/A = Beck Depression Inventory - II Cognitive Affective; BDI-II S= Beck 
Depression Inventory - II Somatic; PHQ-9 = Patient Health Questionnaire - 9 
V=43. 
*p<.05. **p<01 
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be an absolute minimum of five subjects per variable, with the proviso that there are at least 100 
subjects” (p.l40). After excluding participants with greater than 10 missing variables, our sample 
was 12 participants shy of meeting this criterion. Scree plots and interpretability of the factors 
were used to determine the number of factors to be extracted (Streiner, 1994). The EFA initially 
supported a 6-factor solution. However, Streiner (1994) argues that a factor should be comprised 
of at least three variables. In the overall sample, factors 5 and 6 only contained 2 items each with 
factor loadings greater than .300. In addition, Martinussen, Hakamies-Blomqvist, MOller, 
Ozkan,and Lajunen (2013) reported that it is not necessary to apply different DBQ structures to 
different driver groups, with the exception of different age groups. Martinussen et al. also 
suggest that a three and four-factor model was acceptable across subgroups but found a lower fit 
among younger groups. These researchers highlight that additional research needs to be 
conducted examining a factor model for younger groups. Therefore, a forced four-factor EFA 
was conducted on individuals aged 18 to 35. The total number of cases in the data file was 233. 
Together the four-factor solution explained 43.12% of variance. Factor 1 explained 29.17% of 
the variance, while factors 2, 3, and 4, explained 5.89 %, 4.16%, and 3.90%, of the variance, 
respectively. See table 13 for correlations between factors and eigenvalues. See table 14 for DBQ 
items and factor loadings. The same items loaded on each factor as with the whole sample, with 
some variation in the factor loadings for each item. 
Reliability Analyses. Reliability analyses for the four-factor solution for participants 
aged 18 to 35 (« = 235) also demonstrated good to excellent internal consistency, which is 
considered to fall in the good to excellent range (Murphy & Davidshofer, 2005; see table 13). 
Cronbach’s alphas for factors 1, 2, 3, and 4 were .92, .84, .76, and .78, respectively. This 
suggests that our items within each factor measure are likely measuring the same construct. 
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Next, given that there has yet to be a shortened version of the DBQ has been applied to a 
Canadian sample, our goal was to condense the DBQ items to a shortened version (DBQ-SV) 
with 5 items per factor and a total of 20 items. Items were selected based on the five highest 
item-total correlations. For factor 1, item-total correlations ranged from .45 to .68. Items DBQ24, 
DBQ27, DBQ41, DBQ45, and DBQ49 were included for factor 1. These items can be considered 
“Errors” and delineated as perceptual, attention, and information processing errors, including 
misjudgements when driving. Items DBQ3, DBQ4, DBQ8, DBQ 15, and DBQ30 had the highest 
item-total correlations for factor 2 and item-total correlations ranged from .44 to .65. These items 
can be considered “Emotional Violations” or violations that reflect a driver’s style and driving 
habits due to an emotional response. For factor 3, items DBQ 12, DBQ 13, DBQ 16, DBQ32, and 
DBQ37 were included and item-total correlations ranged from .37 to .68. These items can be 
considered “Absent-Mindedness” and delineated as being forgetful or having a low level of 
attention while driving. Lastly, factor 4 items included DBQ 17, DBQ21, DBQ25, DBQ28, and 
DBQ43 with item-total correlations ranging from .40 to .53. These items can be considered 
“Reckless Violations” or disrespectful violations. See Table 15 for descriptive statistics for the 
DBQ-L V and DBQ-SV and table 16 for item-total statistics of the items of the DBQ-SV and 
DBQ-LV. Cronbach’s alphas for short version of factors 1,2, 3, and 4 were .82, .79, .74, and .71, 
respectively (see Table 13). 
Validity Analyses. To investigate validity, the DBQ-SV was correlated to the DBQ-LV 
(49-items). Correlation coefficients between the short and long version were excellent and 
ranged from .91 to .94 (see Table 17). A t-test was calculated to investigate any significant 
differences between the DBQ-LV and DBQ-SV. Results suggested no significant differences on 
the factor scores between the two versions. Each factor, including the total score, for both 
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versions was also correlated with the BDI-II as a measure of discriminant validity. All factors, 
except factor 2, were significantly related to the BDI-II and both versions were consistent. 
Correlation coefficients ranged from .12 to .22 (see Table 18). Correlation coefficients were also 
generated for men and women. Both versions were also consistent across the factors and the total 
scores for men. Correlation coefficients ranged from .16 to .51 (see Table 18). Factor 3 was the 
only factor that was significantly related to the BDI-II for women across both the DBQ-LV and 
DBQ-SV. The total score for the DBQ-SV was also significantly related to the BDI-II for 
women; however, the DBQ-LV total score was not significantly related to the BDI-II for women. 
Scatterplots were generated to depict the relationship between the DBQ-LV and DBQ-SV and 
BDI-II across the total sample, men, and women (see Figure 2). 
As a measure of concurrent validity, the DBQ-LV and DBQ-SV were correlated with the 
simulated drive total score for participants who completed the laboratory session (N= 43). A t- 
test was also generated to investigate any significant differences between the DBQ-LV, DBQ- 
SV, and MRT total score. Results suggested no significant differences on the factor scores 
between the two versions and the MRT scores (see Table 19). Both versions were consistent. 
Correlation coefficients for both versions and the MRT ranged from .03 to .26 (see Table 19). 
Hypothesis 2. We expected to observe that higher levels of antidepressant medication 
use and/or depressive symptoms would predict higher levels of self-reported unsafe driving 
behaviour on the subtests of the shortened version of the DBQ. Multivariable (multiple predictor 
variables) regression models were employed to examine the presence of possible relationships 
between sex, age, depressive symptoms (BDI-II Cognitive/Affective and Somatic symptoms), 
anxiety symptoms (BAI), antidepressant use, and driving errors (Factor 1), emotional violations 
(Factor 2), absent-mindedness (Factor 3), and the sum of the four factors. Factor 4 (Reckless 
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Table 13 
Correlation coefficients between factors, eigenvalues, and Cronbach’s alphas for the 4-factor 
EFA for ages 18-35 {n = 235) 
Factor 1 Factor 2 Factor 3 Factor 4 
Factor 1 (Errors) 1.00 
Factor 2 (Emotional Violations) .360 
Factor 3 (Absent-mindedness) .476 
Factor 4 (Reckless Violations) .399 
Eigenvalues 14.29 
Cronbach’s a (DBQ-LV) .92 
















Note. EFA = Exploratory Factor Analysis; DBQ-LV = Driving Behaviour Questionnaire - Long 












































































































m «N fN vo^ o mmoo 
ON ON m vor^ ^ ^oo 






























































2 b & CO 





















































X 2 c 





































V — o 
■I E'-^ 3^0 





















































































§ o X 
2 c .£ 
^ X X 
- X X 
X 3 £ 
p 2 P 
> 
00 3 tj 






o .£ 5^ 
c X 2 
§ p 
b X 2 O 3 

















8. "5 ® O
00 
P c P 
X -3 p 
-*-> X x 
p tS o 
00 c 3 
'O S o 303 
















— 3 X 
X 
00 


















2 £ i2 
ON O 
CN m 
0“ o" cr" 
XXX 
Q Q Q 
4) £ 
































.2P o W5 2 





























m m o" cr ^ 
X X eT 
















































































































































































































TJ- ^ (S 
o m <s 00 






NO 't" o wo NO 




























































































































































































DEPRESSION, ANTIDEPRESSANTS, AND DRIVING 89 
Table 15 
Descriptive statistics for the DBQ-LF and DBQ-SV 

































* DBQ-LV = Driving Behaviour Questionnaire - Long Version; DBQ-SV = Driving Behaviour 
Questionnaire - Short Version; SD = Standard Deviation; n = 235. 
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Table 16 
Item-total statistics for the DBQ-SV 
Factor (items) Item-total correlation Cronbach’s a if item deleted 
1. Errors 
DBQ24 “Nearly hit car in 
front” 
DBQ27 “Fail to notice 
pedestrian ” 
DBQ41 ““Overtake a 
vehicle ” 
DBQ45 “Fail to notice 
pedestrian ” 
DBQ49 “Misjudge crossing 
interval” 
2. Emotional Violations 
DBQ3 “Impatient with slow 
driver” 
DBQ4 “Drive fast with 
headlights on low at night” 
DBQ8 “Preoccupied and slam 
on brakes ” 
DBQ15 “Frustration causing 
you to over-take in risky 
situation ” 
DBQ20 “Deliberately 
disregard speed limit” 
3. Absent-Mindedness 
DBQ12 “Realize no clear 
recollection of road” 
DBQ12 “Missyour exit” 
DBQ16 “Wake up andfind 
self on wrong route ” 
DBQ32 “ Plan route badly 
DBQ37 “Exit from highway 
on wrong road” 
4. Reckless Violations 
DBQ17 “Cross lights on red” 
DBQ21 “Drive when 
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DBQ25 “Drive home after .46 .76 
BACover limit” 
DBQ28 “Park in no parking .52 .75 
area ” 
DBQ43 “Disregard red .49 .75 
lights ”  
Note. DBQ-SV = Driving Behaviour Questionnaire - Short Version; N= 235. 
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Table 17 
Correlations (r) and t-tests between the DBQ-LV and DBQ-SV 





.91 [.89, .93] 
.94 [.93, .95] 
.94 [.92, .95] 













Note. DBQ-LV = Driving Behaviour Questionnaire - Long Version; DBQ-SV = Driving 
Behaviour Questionnaire - Short Version; Cl = Confidence Interval 
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Table 18 
Correlations (r) between the DBQ-LV and DBQ-SV with the BDI-II total score 
2 Factors Total sample 
r [95% Cl] 
Women^ 
r [95% Cl] 
Men^ 
r [95%CI] 
Factor 1 - DBQ-LV 
Factor 1 - DBQ-SV 
Factor 2 - DBQ-LV 
Factor 2 - DBQ-SV 
Factor 3 - DBQ-LV 
Factor 3 - DBQ-SV 
Factor 4 - DBQ-LV 
Factor 4 - DBQ-SV 
Total Score - DBQ-LV 
Total Score - DBQ-SV 
.17* [.04, .30] 
.17* [.04, .30] 
.12 [-.01,.24] 
.13 [.00, .25] 
.21** [.09, .33] 
.22** [.09, .34] 
.21** [.08, .33] 
.18** [.05, .30] 
.19** [.07, .33] 
.21** [.08, .33] 
.07 [-.08, .22] 
.10 [-.05, .24] 
.10 [-.05, .24] 
.12 [-.02, .27] 
.19** [.05, .33] 
.22** [.08, .35] 
.12 [-.03, .26] 
.09 [-.06, .23] 
.11 [-.04, .26] 
.16* [.01, .30] 
.51** [.23, .71] 
.41** [.12, .63] 
.18 [-.13, .46] 
.16 [-.14, .44] 
.21 [-.09, .48] 
.16 [-.14, .44] 
.42** [.12, .64] 
.33* [.03, .58] 
.48** [.18, .70] 
.34* [.03, .59] 
Note. DBQ-LV = Driving Behaviour Questionnaire - Long Version; DBQ-SV = Driving 
Behaviour Questionnaire - Short Version; BDI-II = Beck Depression Inventory II; ’N = 233; 
^n = 45;\=\S6 
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DBQ-LV to BDI-II for total sample DBQ-SV to BDI-II for total sample 
DBQ-LV to BDI-II for men DBQ-SV to BDI-II for men 
DBQ-LV to BDI-II for women DBQ-SV to BDI-II for women 
Figure 2. Scatterplots of the DBQ- LV and DBQ-SV and BDI-II total scores across the total 
sample (Total N =229), men (/? = 45), and women (n = 184). 
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Table 19 
Correlations (r) and t-tests between the DBQ-LV and DBQ-SV and MRT 
Factors r [95% Cl] t-score df 
DBQ-LV& DBQ-SV& DBQ-LV & 
MRT MRT DBQ-SV 
Factor 1 .04 [-.26, .34] .03[-.27,.33] .91 [-.11, .14] .181 40 .857 
Factor 2 .07 [-.24, .37] .10[-.21,.39] .94 [-.13, .08] -.526 39 .602 
Factor 3 .06 [-.25, .35] .05[-.25,.35] .94 [-.11, .11] .053 40 .958 
Factor 4 .25 [-.05, .52] .23[-.08,.50] .93 [-.09, 14] .423 39 .674 
Total .25 [-.07, .51] .26[-.06,.52] .96 [-.11, .09] -.239 38 .812 
Note. DBQ-LV = Driving Behaviour Questionnaire - Long Version; DBQ-SV == Driving 
Behaviour Questionnaire - Short Version; MRT = Manitoba Road Test; Cl = Confidence 
Interval 
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Violations) was not included as it was not hypothesized that depressive and anxious symptoms 
would be related to reckless behaviour. Centering, the practice of subtracting a constant from 
predictors before fitting the model, was applied to age. The intercept is a representation of the 
value of the outcome when all of the predictors are valued at zero. Centering the predictors is 
important as it changes the meaning of an intercept due to the fact that some predictors do not 
logically have a value of zero (e.g., an age of zero; Tabachnick & Fidell, 2001). Therefore, age 
was centered at 18, which was the minimum value. See figure 3 for residual plots of predicted 
value of factors 1 to 3 and DBQ total with unstandardized residuals. See Figure 4 for histograms 
of unstandardized residuals. 
Factor 1 (Errors), Tables 20 and 21 display results of two regression models predicting 
Factor 1 (Errors). The first model, which includes the BAI as a predictor, predicting Factor 1 
(Errors) was not statistically significant, F(6, 228) = 1.64,/? = .14, and accounted for 4% (2% 
adjusted) of the variability in Factor 1. No individual variables significantly predicted self- 
reported unsafe driving behaviour on factor 1 (see Table 20). Therefore, a second model was 
performed without the BAI as a predictor variable. The second model predicting Factor 1 
(Errors) was not statistically significant, F(8, 228) = \ .62,p = .12, and accounted for 6% (2% 
adjusted) of the variability in Factor 1 (see Table 21). 
Factor 2 (Emotional Violations). Tables 22 and 23 display results of two regression models 
predicting emotional violations. The first model includes the BAI as a predictor variable, and 
was not statistically significant, F(6, 228) = .98, p = .44. This model accounted for 3% (0% 
adjusted) of the variability in Factor 2 (see Table 22). A second model was performed without 
the BAI as a predictor variable. The second model was also not statistically significant, F(8, 228) 
= 1.08, p = .38 and accounted for 4% (0% adjusted) of the variability in Factor 2 emotional 
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Residual Plot Facttr 1 Residual Plot Factor 2 
Residual Plot Factor 3 
Residual Plot DRQ Total 
^ 40^000- 
2 20.00000- 
10.00000 15.00000 20.00000 25.00000 20.00000 
UfittaiKlanllicd Predicted Value 
Figure 3. Plots of the predicted value of factors 1,2, 3, and DBQ total with unstandardized 
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Residuals: Factor 1 Residuals: Factor 2 
Residuals: Factor 3 Residuals: DBQ Total 
Figure 4. Histograms of unstandardized residuals for factors and DBQ total. The arrows 
represent the same participant (Factor I D = O.11; DBQ total D = 0.07). 
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Table 20 
Standard multivariable regression of age, sex, BDI-II Cognitive/Affective, BDI-II Somatic, BAI 
Total, and Antidepressant use on Factor 1 (Errors; N = 229) pooled data 
Variable (Pooled data) B SEB 95% Cl t-score p-value 
age 0.01 0.05 [-0.10,0.10] 





0.02 0.04 [-0.07,0.11] 
0.09 0.10 [-0.10,0.29] 
0.02 0.03 [-0.03,0.07] 













Note. = .04; Adjusted = .02; “ BDI-II C/A = Beck Depression Inventory - II Cognitive 
Affective; BDI-II S = Beck Depression Inventory - II Somatic; BAI = Beck Depression 
Inventory. The raw score for age was centered on a value of 18. 
*p<.05, **p<.0l. 
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Table 21 
Standard multivariable regression of age, sex, BDI-II Cognitive/Affective, BDI-II Somatic, and 
Antidepressant use on Factor 1 (Errors; N = 229) pooled data 
Variable (Pooled data) B SEB 95% Cl t-score p-value 
age -0.01 0.05 [-0.11,0.09] 







0.02 0.04 [-0.02,0.07] 
0.07 0.11 [-0.04,0.17] 
-0.95 0.66 [-1.61,-0.29] 
0.07 0.11 [-0.15,0.30] 
0.06 0.29 [-0.51,0.62] 

















Note. = .06; Adjusted = .02; BDI-II C/A = Beck Depression Inventory - II Cognitive 
Affective; BDI-II S = Beck Depression Inventory - II Somatic; antidep = any antidepressant; 
®The raw score for age was centered on a value of 18. 
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Table 22 
Standard multivariable regression of age, sex, BDI-II Cognitive/Affective, BDI-II Somatic, BAI 
Total, and Antidepressant use on Factor 2 (Emotional Violations; N = 229) pooled data 
Variable (Pooled data) B SEB 95% Cl t-score p-value 
age -0.09 0.08 [-0.24,0.07] 





-0.01 0.07 [-0.14,0.14] 
0.20 0.16 [-0.12,0.52] 













Note. ^ = .03; Adjusted = 0;^ BDI-II C/A = Beck Depression Inventory - II Cognitive 
Affective; BDI-II S = Beck Depression Inventory - II Somatic; BAI = Beck Depression 
Inventory. The raw score for age was centered on a value of 18. 
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violations (see Table 23). Similar to the model predicting Factor 1, no significant individual 
predictors of interest emerged. 
Factor 3 (Absent-Mindedness), The results of two regression models predicting absent- 
mindedness (Tables 24 and 25) were generated. The first model was statistically significant, F(6, 
228) = 2.73,/? < .01, and accounted for 7% (4% adjusted) of the variability in Factor 3. Age {B = 
.12) was a significant predictor of absent-mindedness, such that increasing age was associated 
with an increase in absent-minded driving behaviour. The cognitive/affective component of the 
BDI-II (B = .12) was also a significant predictor of absent-mindedness suggesting that increased 
cognitive/affective impairments were associated with absent-minded driving behaviour. The 
second model predicting Factor 3 (Absent-mindedness) was also statistically significant, F(8, 
228) = 2.15,/? =.03, and accounted for 7% (4% adjusted) of the variability in Factor 3 (Absent- 
mindedness). Similar to model 1, Age {B= .\2) and the cognitive/affective component of the 
BDI-II (^ = .12) were significant predictors of absent-mindedness. These results suggest 
increasing age and increased cognitive/affective impairments are associated with absent- 
mindedness on the DBQ. 
Sum of factors. The results of two regression models predicting the sum of the four 
factors (Tables 26 and 27) were generated. The first model includes the BAI as a predictor 
variable, which was not statistically significant, F(6, 228) = 1.85,/? = .09, and accounted for 5% 
(2% adjusted) of the variability in the sum of the four factors. The second model predicting the 
sum of the four factors was also not statistically significant, i^(8, 228) = 1.52, /? = . 15, and 
accounted for 5% (2% adjusted) of the variability in the sum of the four factors. Similar to the 
models predicting Factors 1 and 2, no significant individual predictors of interest emerged. 
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Hypothesis 3. We expected to observe that higher levels of antidepressant medication 
use and/or depressive symptoms would be related to increased impairments on measures of 
attention (CRSD-ANT), executive functioning (TMT), visual perceptual ability (MVPT-3), and 
visual information processing (UFOV). 
CRSD-ANT, The results of four regression models predicting the CRSD-ANT median 
response time (RT), alerting, orienting, and conflict scores (Tables 28 to 31) were generated. 
Median RT was used instead of mean RT because raw RT distributions are known to be 
positively skewed (Williams & Zimmerman, 1996). None of the overall models with ANT 
variables as outcomes were statistically significant (See F-ratios plus ^ and adjusted values 
in Tables 28 to 31). However, the PHQ-9 {B = -2.48) and BDI-II Cognitive Affective {B = 3.45) 
scores were significantly associated with the alerting score from the CRSD-ANT. See figure 5 
for histograms of unstandardized residuals. See figure 6 for residual plots of CRSD-ANT median 
response time (RT), alerting, orienting, and conflict scores with unstandardized residuals. 
TMT. The results of regression models predicting the TMT-A or TMT-B total score (see 
Table 32 and 33) were generated. The models with the TMT-A or TMT-B total score as an 
outcome were not statistically significant (See F-ratios plus P? and adjusted ^ values in Tables 
32 and 33). See figures 7 and 8 for histograms of unstandardized residuals and residual plots of 
the TMT-A and TMT-B with unstandardized residuals, respectively. 
MVPT-3. None of the models with MVPT-3 variables as outcomes were statistically 
significant (See F-ratios plus F? and adjusted ^ values in Tables 34 and 35). The BDI-II 
Cognitive Affective scores were significantly associated with the standard score {B = 2.02) and 
errors {B = -.65) score from the MVPT-3. See Figure 9 for histograms of unstandardized 
residuals. 
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Table 23 
Standard multivariable regression of age, sex, BDI-II Cognitive/Affective, BDI-II Somatic, and 
Antidepressant use on Factor 2 (Emotional Violations; N = 229) pooled data 
Variable B SEB 95% Cl t-score p-value 
age^ -0.09 
sex (Male = 1, Female = 0) -0.96 
BDI-II C/A 0.04 
BDI-II S 0.12 
Antidepressant use -0.87 
sexBYBDI-II C/A -0.24 


































Note. = .04; Adjusted R^ = 0; ® BDI-II C/A = Beck Depression Inventory - II Cognitive 
Affective; BDI-II S = Beck Depression Inventory - II Somatic; antidep = any antidepressant; 
The raw score for age was centered on a value of 18. 
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Table 24 
Standard multivariable regression of age, sex, BDI-II Cognitive/Affective, BDI-II Somatic, BAI 
Total, and Antidepressant use on Factor 3 (Absent-Mindedness; N = 229) pooled data 
Variable (Pooled data) B SEB 95% Cl t-score p-value 
age 0.12* 0.06 [0.01,0.24] 





0.12* 0.05 [0.01,0.23] 
-0.05 0.12 [-0.29,0.19] 













Note. = .07; Adjusted = ,04; ^ BDI-II C/A = Beck Depression Inventory - II Cognitive 
Affective; BDI-II S = Beck Depression Inventory - II Somatic; BAI = Beck Depression 
Inventory. The raw score for age was centered on a value of 18. 
*/7<.05. **/7<.01. 
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Table 25 
Standard multivariable regression of age, sex, BDI-II Cognitive/Affective, BDI-II Somatic, and 
Antidepressant use on Factor 3 (Absent-mindedness; N = 229) pooled data 
Variable B SEB 95% Cl t-score p-value 
age^ 0.12* 
sex (Male =1, -0.41 
Female = 0) 
BDI-II C/A 0.12* 
BDI-II S -0.03 
Antidepressant use -0.64 
sexBYBDI-II CA -0.02 
sexBYBDI-II S -0.05 

































Note. B? = .07; Adjusted ^ = .04; ^ BDI-II C/A = Beck Depression Inventory - II Cognitive 
Affective; BDI-II S = Beck Depression Inventory - II Somatic; antidep = any antidepressant; 
The raw score for age was centered on a value of 18. 
*p<05. **p <.01. 
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Table 26 
Standard multivariable regression of age, sex, BDI-II Cognitive/Affective, BDI-II Somatic, BAI 
Total, and Antidepressant use on the sum of the four factors (DBQ-Total; N = 229) pooled data 
Variable (Pooled data) B SEB 95% Cl t-score p-value 
age 0.19 0.19 [-0.17,0.55] 1.02 .31 





0.18 0.17 [-0.14,0.51] 1.10 
0.28 0.37 [-0.46, 1.01] 0.74 
0.03 0.10 [-0.16,0.23] 0.35 





Note, = .05; Adjusted = .02; ^ BDI-II C/A = Beck Depression Inventory - II Cognitive 
Affective; BDI-II S = Beck Depression Inventory - II Somatic; BAI = Beck Depression 
Inventory. The raw score for age was centered on a value of 18. 
DEPRESSION, ANTIDEPRESSANTS, AND DRIVING 108 
Table 27 
Standard multivariable regression of age, sex, BDI-II Cognitive/Affective, BDI-II Somatic, and 
Antidepressant use on the pooled data of the sum of the four factors (N = 229) pooled data 
Variable B SEB 95% Cl t-score p-value 
age 















































Note. = .05; Adjusted ^ = .02; ^ BDI-II C/A = Beck Depression Inventory - II Cognitive 
Affective; BDI-II S = Beck Depression Inventory - II Somatic; antidep = any antidepressant; 
The raw score for age was centered on a value of 18. 
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Table 28 
Ordinary least squares regression of PHQ9, BDI-II Cognitive/Affective and BDI-II Somatic for 
the CRSD-ANT median response time 
Variable B SE B f 95% Cl t-sore p 
PHQ-9 -1.76 2.67 -0.13 [-7.16,3.65] -0.66 .52 
BDI-II C/A 2.11 3.16 0.15 [-4.27,8.49] 0.67 .51 
BDI-II S -3.70 3.99 -0.18 [-11.77,4.36] -0.93 .34 
Note. F(3,39) = 0.54, p = .66; = .04; Adjusted = -.03; N = 43; PHQ-9 = Patient Health 
Questionnaire - 9; BDI-II C/A = Beck Depression Inventory - II Cognitive Affective; BDI-II S 
= Beck Depression Inventory - II Somatic. 
*p <.05. ** p <.01. 
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Table 29 
Ordinary least squares regression of PHQ9, BDl-Il Cognitive/Affective and BDl-11 Somatic for 
the CRSD-ANT alerting score 
Variable B SE B fi 95% Cl t-score p 
PHQ-9 -2.48 1.26 -0.38* [-5.04, .08] -1.96 .05 
BDI-IIC/A 3.45 1.49 0.48* [0.43,6.47] 2.31 .03 
BDI-IIS -1.75 1.89 -0.17 [-5.57,2.07] -.93 .36 
Note. F(3,39) = 2.15, p =. 11; «■' =. 14; Adjusted = .07; JV = 43; PHQ-9 = Patient Health 
Questionnaire - 9; BDI-II C/A = Beck Depression Inventory - II Cognitive Affective; BDI-II S 
- Beck Depression Inventory - II Somatic. 
*p<.05. **/7<.01. 
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Table 30 
Ordinary least squares regression of PHQ9, BDl-II Cognitive/Affective and BDI-II Somatic for 
the CRSD-ANT orienting score 
Variable B SE B fi 95% Cl t-score p 
PHQ-9 -1.97 1.68 -0.22 [-5.37,1.44] -1.17 .25 
BDI-II C/A 2.38 1.99 0.25 [-1.64,6.40] 1.49 .24 
BDI-II S 3.74 2.51 0.23 [-1.34,8.82] 1.20 .15 
Note. fl(3, 39) = 2.17, p = . 11; = . 14; Adjusted R^ = M;N = 43; PHQ-9 = Patient Health 
Questionnaire - 9; BDI-II C/A = Beck Depression Inventory - II Cognitive Affective; BDI-II S 
= Beck Depression Inventory - II Somatic. 
*p <.05. ** p <.01. 
DEPRESSION, ANTIDEPRESSANTS, AND DRIVING II2 
Table 31 
Ordinary least squares regression of PHQ9, BDI-II Cognitive/Affective and BDI-II Somatic for 
the CRSD-ANT conflict score 
Variable B SE B fi 95% Cl t-score p 
PHQ-9 1.98 1.49 0.27 [-1.04,5.00] 1.33 .19 
BDI-II C/A 0.31 1.76 0.04 [-3.26,3.87] 0.17 .86 
BDI-II S -1.70 2.23 -0.15 [-6.21,2.80] -0.77 .45 
Note. F(3, 39) = 0.88 p = .46; = .06; Adjusted = 43; PHQ-9 = Patient Health 
Questionnaire - 9; BDI-II C/A = Beck Depression Inventory - II Cognitive Affective; BDI-II S 
= Beck Depression Inventory - II Somatic. 
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Histogram 
Dependent Variable: Median RT (all correct trials) 
Histogram 
Dependent Variable: Orienting 
Histogram 
Dependent Variable: Alerting 
Figure 5. Histograms of unstandardized residuals for the CRSD-ANT median response time 
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Scatterplot 
Dependent Variable: Median RT (all correct trials) 
Regression Standardized Predicted Value 
Scatterplot 
Dependent Variable: Alerting 
Scatterplot 
Dependent Variable: Orienting 
Scatterplot 
Dependent Variable: Conflict 
Figure 6. Plots of the predicted value of the CRSD-ANT median response time (RT), alerting, 
orienting, and conflict scores with unstandardized residuals. 
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Table 32 
Ordinary least squares regression ofPHQ9, BDl-II Cognitive/Affective and BDI-II Somatic for 
the TMT-A score 
Variable B SE B f 95% Cl t-score p 
PHQ-9 -0.36 0.57 -0.13 [-1.51,0.79] -0.64 .53 
BDI-II C/A 0.28 0.67 0.09 [-1.08,1.63] 0.41 .68 
BDI-II S 0.17 0.85 0.04 [-1.54,1.88] 0.20 .84 
Note. i^3,39) = 0.15 p = .93; /f' = .01; Adjusted = -.06; N = 43; PHQ-9 = Patient Health 
Questionnaire - 9; BDI-II C/A = Beck Depression Inventory - II Cognitive Affective; BDI-II S 
= Beck Depression Inventory - II Somatic. 
*p <.05. **p <.01. 
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Table 33 
Ordinary least squares regression of PHQ9, BDI-II Cognitive/Affective and BDl-Il Somatic for 
the TMT-B score 
Variable B SEB fi 95% Cl t-score p 
PHQ-9 -1.97 1.31 -0.29 [-4.61,0.68] -1.50 .14 
BDI-II C/A 2.17 1.55 0.30 [-0.96,5.30] 1.40 .17 
BDI-II S 2.13 1.95 0.21 [-1.82,6.08] 1.09 .28 
Note. F(3,39) = 1.83 p =. 16; /f' = . 12; Adjusted F^=M\N = 43; PHQ-9 = Patient Health 
Questionnaire - 9; BDI-II C/A = Beck Depression Inventory - II Cognitive Affective; BDI-II S 
= Beck Depression Inventory - II Somatic. 
*p <.05. ** p<.0\. 
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Histogram 
Dependent Variable: (Ql: Trails A Total Time) 
Histogram 
Dependent Variable: (Q2: Trails B Total Time) 
Figure 7. Histograms of unstandardized residuals for the TMT-A and TMT-B. 
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Scatterplot 
Dependent Variable; (Ql: Trails A Total Time) 
Scatterplot 
Dependent Variable: (Q2: Trails B Total Time) 
Figure 8. Plots of the predicted value of TMT-A and TMT-B with unstandardized residuals. 
DEPRESSION, ANTIDEPRESSANTS, AND DRIVING 119 
Table 34 
Ordinary least squares regression of PHQ9, BDl-II Cognitive/Affective and BDI-II Somatic for 
the MVPT-3 standard score 
Variable B SEB fi 95% Cl t-score p 
PHQ-9 -1.36 0.86 -0.30 [-3.10,0.38] -1.58 .12 
BDI-II C/A 2.02 1.02 0.42* [-0.04,4.08] 1.98 .05 
BDI-II S -2.06 1.29 -0.30 [-4.66,0.54] -1.60 .12 
Note. F(3,39) = 2.06,p = .12; = .14; Adjusted R" = .07; N = 43; PHQ-9 = Patient Health 
Questionnaire - 9; BDI-II C/A = Beck Depression Inventory - II Cognitive Affective; BDI-II S 
= Beck Depression Inventory - II Somatic; MVPT-3 = Motor-Free Visual Perception Test: Third 
edition 
*p <.05. ** p <.01. 
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Table 35 
Ordinary least squares regression ofPHQ9, BDI-II Cognitive/Affective and BDI-Il Somatic for 
the MVPT-3 errors. 
Variable B SE B fi 95% Cl t-score p 
PHQ-9 0.44 0.23 0.36 [-0.03,0.91] 1.89 .07 
BDI-II C/A -0.65 0.28 -0.49* [-2.35,0.02] -2.35 .02 
BDI-II S 0.52 0.35 0.28 [-0.18,1.23] 1.50 .14 
Note. F(3,39) = 2.47,p = .08; = .16; Adjusted = AO; N = 43; PHQ-9 = Patient Health 
Questionnaire - 9; BDI-II C/A = Beck Depression Inventory - II Cognitive Affective; BDI-II S 
= Beck Depression Inventory - II Somatic. 
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Histogram 
Dependent Variable: (MVPT Standard Score) 
Histogram 
Dependent Variable: (MVPT Errors) 
Figure 9. Histograms of unstandardized residuals for the MVPT standard score and MVPT 
errors. 
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See Figure 10 residual plots of MVPT-3 errors and MVPT-3 standard scores with unstandardized 
residuals. 
UFOV, The results of two regression models predicting the UFOV sum score and UFOV 
divided attention score (Tables 36 and 37) were generated. None of the models with UFOV 
variables as outcomes were statistically significant (See F-ratios plus and adjusted values 
in Tables 36 and 37). See Figures 11 and 12 for histograms of unstandardized residuals and 
residual plots, respectively. 
Hypothesis 4. We expected to observe that depressive symptoms would predict poorer 
driving performance on the driving simulator. However, given that only 2 participants who 
participated in the laboratory session were taking an antidepressant (both were taking an SSRI), 
we excluded antidepressant use from these analyses. 
MRT. The results of one regression model predicting the MRT demerit points score 
(Table 38) was generated. The model with the MRT demerit points score as an outcome was not 
statistically significant (See F-ratios plus R^ and adjusted R^ values in Table 38). See also figures 
13 and 14 for histograms of unstandardized residuals and residual plots, respectively. 
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Scanerplot Scatterplot 
Dependent Variable: (MVPT Standard Score) Dependent Variable: (MVPT Errors) 
Regression Standardized Predicted Value Regression Standardized Predicted Value 
Figure 10. Plots of the predicted value of MVPT standard score and MVPT errors with 
unstandardized residuals. 
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Table 36 
Ordinary least squares regression of PHQ9, BDI-II Cognitive/Affective and BDI-Il Somatic for 
the UFOVsum score 
Variable B SEB fi 95% Cl t-score p 
PHQ-9 1.22 1.40 0.18 [-1.60,4.04] 0.88 .39 
BDI-II C/A -1.32 1.65 -0.18 [-4.66,2.01] -0.80 .42 
BDI-II S 1.61 2.08 0.15 [-2.61,5.82] 0.77 .45 
Note. F(3, 39) = .56, p = .65; = .04; Adjusted = -0.03; N = 43; PHQ-9 = Patient Health 
Questionnaire - 9; BDI-II C/A = Beck Depression Inventory - II Cognitive Affective; BDI-II S 
= Beck Depression Inventory - II Somatic. 
♦jc><.05. **/7<.01. 
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Table 37 
Ordinary least squares regression of PHQ9, BDI-II Cognitive/Affective and BDI-II Somatic for 
the UFOV divided attention score 
Variable B SEB fi 95% Cl t-score p 
PHQ-9 -0.34 0.45 -0.15 [-1.24,0.56] -0.76 .45 
BDI-II C/A -0.28 0.51 -0.12 [-1.34,0.79] -0.53 .60 
BDI-II S 1.12 0.67 0.32 [-0.23,2.46] 1.68 .10 
Note. F(3, 39) = \ .02,p = .39; = .07; Adjusted = .01; N = 43; PHQ-9 = Patient Health 
Questionnaire - 9; BDI-II C/A = Beck Depression Inventory - II Cognitive Affective; BDI-II S 
= Beck Depression Inventory - II Somatic. 
*/7<.05. **/7<.01. 
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Histogram Histogram 
Dependent Variable: ufov.sum Dependent Variable: UFOV-2 (divided attention) 
Figure 11. Histograms of unstandardized residuals for the UFOV sum and UFOV divided 
attention scores. 
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Scanerplot 
Dependent Variable: ufov.sum 
Scatterplot 
Dependent Variable: UFOV-2 (divided attention) 
Figure 12. Plots of the predicted value of UFOV sum and UFOV divided attention score with 
unstandardized residuals. 
DEPRESSION, ANTIDEPRESSANTS, AND DRIVING 128 
Table 38 
Ordinary least squares regression of PHQ9, BDl-II Cognitive/Affective and BDI-II Somatic for 
the MRT (Demerit points) score 
Variable B SEB fi 95% Cl t-score p 
PHQ-9 1.64 1.66 0.20 [-1.70,4.99] 0.99 .33 
BDI-IIC/A -2.67 1.96 -0.30 [-6.62,1.29] -1.36 .18 
BDI-II S 0.45 2.47 0.04 [-4.55,5.44] 0.18 .86 
Note. F(3,39) = 0.70, p = .56; R' = .05; Adjusted R" = -0.02; N = 43; PHQ-9 = Patient Health 
Questionnaire - 9; BDI-II C/A = Beck Depression Inventory - II Cognitive Affective; BDI-II S 
~ Beck Depression Inventory - II Somatic. 
V< 05. **p<.0l. 
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Histogram 
Dependent Variable: Total Demerits On Manitoba Road Test 
Regression Standardized Residual 
Figure 13. Histogram of unstandardized residuals for the MRT. 
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Scatterplot 





1 I i i r 
2 10 12 
Regression Standardized Predicted Value 
Figure 14. Plot of the predicted value of the MRT with unstandardized residuals. 
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Discussion 
Research on the topic of the influence of Major Depressive Disorder (MDD) and the 
antidepressants used to treat MDD on driving performance has reported contradictory results (see 
Barbone et al., 1998; Leveille et al., 1994; Wingen et al., 2005). MDD can lead to cognitive and 
psychomotor disturbances such as impairments in executive functions, attentional deficits, 
restlessness, motivational deficits, and slowed thought processes (APA, 2013; Brebion et al., 
1997; Egeland et al., 2003; Hill et al., 2004; Ravnkilde et al., 2002), which can be detrimental to 
the task of driving. Likewise, antidepressant medications can cause deficits to psychomotor skills 
(Ramaekers, 2003; Rapoport & Banina, 2007) but can also improve cognition by improving 
mood, attention, and executive functions in the short term (Impey & Baldwin, 2013). Therefore, 
it can be difficult to ascertain if any impairments in driving function are the result of 
antidepressant medications or MDD itself (Hetland & Carr, 2014). Therefore, it was logical to 
conduct additional research on this topic using an ecologically valid, a driving simulator. In 
addition, the factor structure of the Driver Behaviour Questionnaire (DBQ) has been inconsistent 
across younger age groups. To the best of the authors’ knowledge, previous studies have not 
examined the psychometric properties of a shortened version of the DBQ in a younger Canadian 
sample. 
Main Hypotheses 
Hypothesis 1. We aimed to create a shortened version of the DBQ in a younger 
Canadian sample. We expected to observe good to excellent psychometric properties in this 
shorter version of the DBQ, Murphy and Davidshofer (2005) and Streiner (2003) recommend 
reliability estimates of ,80, and estimates above ,90 to be redundant. Furthermore, Murphy 
and Davidshofer (2005) recommend validity coefficients of ,30 and higher. 
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Previous research on the factor structure of the DBQ with younger participants has 
revealed contradictory findings (see Martinussen et al., 2013 & Rimmd, 2002). Similar to 
Martinuseen and colleagues (2013), our findings supported a four-factor solution using the 50- 
item DBQ among Canadian participants aged 18 to 35. All factor loadings were greater than .30 
(Streiner, 1994). We also created a shortened version (DBQ-SV) by selecting the five highest 
item-total correlations for each factor, totalling 20 items for the shortened version. The highest 
item-total correlations ranged from .37 to .68 across the four factors. Each of the four factors 
corresponds to different aspects of driver behaviour. Factor 1 is considered “Errors” and the 
items are delineated by perceptual, attentional, and/or information processing errors. Factor 2 can 
be considered “Emotional Violations” that reflect a driver’s style and habits to an emotional 
response to a particular situation. In contrast, factor 3 corresponds to “Absent-Mindedness” or 
being forgetful and having poor attention while driving. Lastly, factor 4 is considered “Reckless 
Violations” or disrespectful violations. 
Our study adds to the literature as we examined the DBQ structure in a younger Canadian 
population. Cordazzo, Scialfa, Bubric, and Ross (2014) conducted a principal components 
analysis (using varimax rotation) of the 36-item DBQ using two Canadian samples including a 
younger {M= 20.9 years; SD = 2.1 years) and an older (M= 60.6 years; SD = 13.8) sample. To 
the best of our knowledge, this is the only other study examining the DBQ structure in a 
Canadian study. In contrast to our four-factor solution, Cordazzo et al. reported a two-factor 
solution that explained 27.06% of the variance for errors and violations but not lapses. However, 
Cordazzo et al. did not compare age groups. The only reported finding pertaining to age was that 
age was negatively related to violations (fi = -0.4, p < .01). Furthermore, Cordazzo et al. (2014) 
found that violations for the total sample were significantly related to self-reported collisions (fi 
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= 0.3; p < .001). However, they further highlight that the correlations were small in magnitude 
and have “no predictive utility for collision risk.” (p. 103). In addition, given that Cordazzo et al. 
relied solely on self-report data, our study adds to Cordazzo et al.’s findings as we collected 
simulated drive data in addition to self-report data. In contrast to Cordazzo et al.’s self-report 
data, our study revealed that the simulated drive total score was not significantly related to either 
the DBQ-LV or DBQ-SV across all four factors, including violations (Correlation coefficients 
ranged from .03 to .26; see Table 19). 
Martinussen and Prato (2014) also aimed to examine age and the DBQ. These researchers 
identified sub-groups of drivers who engage in dangerous acts while driving by using the original 
(50-item) 3-factor structure of the DBQ including errors, lapses, and violations. One factor that 
contributed to the groups was age. The group of “violating unsafe drivers” was composed mostly 
of younger drivers. The average age of this group was 39.3 years (SD = 14.1). These drivers self- 
reported the lowest safety skills (M= -0.7; SD = 0.8), and highest frequency of violations (M= 
1.4; SD = 0.9) on the DBQ. In addition, this group reported the highest frequency of accidents 
(M= 0.6; SD = 1.0), parking fines (M= 1.1; iSD = 3.9), and speeding fines (M= 0.4; SD = 0.9) 
over the past 3 years. This study suggests a different driving profile for younger participants. 
However, it is important to consider that Martinussen and Prato (2014) defined “younger 
drivers” as below the age of 55 and the maximum age of participants in our study was age 35. 
Furthermore, our study revealed a 4-factor solution and Martinussen and Prato examined the 
original 3-factor DBQ solution. 
We also examined reliability and validity indices across the 4-factor solution. Cronbach’s 
alpha reliability estimates fell in the good to excellent range (.71 to .82) and no estimate was 
above .90 and therefore this reduces the risk of redundancy. Correlation coefficients between the 
DEPRESSION, ANTIDEPRESSANTS, AND DRIVING 134 
DBQ-LV and DBQ-SV fell in the excellent range suggesting that the shortened version 
demonstrates convergent validity with the longer version. Each factor also demonstrated 
discriminant validity when correlated with the BDI-II. Driving errors were significantly related 
to the total BDI-II scores across the total sample and for men only. This suggests that for women, 
self-reported perceptual, attentional, and/or information processing driving errors are not 
significantly related to depressive symptoms. This finding is surprising given that MDD is 
related to slowed attentional and information processing (Brebion et al., 1997; Egeland et al., 
2003). One explanation for this may be that young women tend to report less driving errors 
compared to men on the DBQ (Blockey & Hartley, 1995). Across both the long version and short 
version, Emotional Violations were not statistically related to the BDI-II, which provides 
evidence of discriminant validity. This finding is also surprising; however, one explanation for 
this is that the items composing this scale generally reflect irritability while driving. On the BDI- 
II, two items specifically assess agitation and irritability. A closer examination suggests that only 
a minority of participants felt agitated (9%). Absent-minded driving was significantly related to 
the BDI-II across both versions and for the total sample and women, and approached 
significance for men. Reckless violations were significantly and positively associated with the 
BDI-II across both versions for the total sample, men, and across the DBQ-SV for women. The 
DBQ-LV approached significance for women. In sum, these results suggest that the DBQ-LV 
and DBQ-LV demonstrated good discriminant validity with the BDI-II. 
Hypothesis 2. We expected to observe that higher levels of antidepressant medication 
use and/or depressive symptoms would predict higher levels of self-reported unsafe driving 
behaviour on the subtests of the shortened version of the DBQ, with the exception of the items 
pertaining to aggressive violations. 
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MDD can induce both cognitive and affective symptoms and impairments in functioning 
such as depressed mood, weight changes, sleep difficulties, psychomotor retardation, loss of 
energy, feelings of worthlessness and guilt, irritability, and suicidal ideation (APA, 2013). These 
symptoms tend to be prevalent in young adult populations (Eisenberg et al., 2007; Price et al., 
2006; Takahashi & Kitamura, 2000). MDD is also highly comorbid with anxiety disorders and 
there is contention in the literature as to whether or not anxiety and depression are distinct 
disorders as there is a large amount of overlap between symptoms (APA, 2013; Beck et al., 
1996; Watson, 2005). Moreover, antidepressant medications are associated with deficits in 
psychomotor skills such as lethargy, slower reaction times, and reduced alertness (Ramaekers, 
2003). Given that the task of driving a vehicle requires sound cognition, attention, and 
psychomotor functioning (Tanida & Poeppel, 2006), is it is logical to expect that MDD 
symptoms could also impair driving performance. To the best of our knowledge, no study has 
examined the influence of MDD and antidepressant medications on self-reported driving 
behaviour using the DBQ as a dependent measure. 
Our findings suggest that Factor 1 is composed of 5-items that can be considered driving 
errors, which are errors in perceptual, attention, information processing, and misjudgements 
when driving. In addition, factor 2 is composed of 5-items and is considered “Emotional 
violations” which reflect driving style and habits due to an emotional response. For both factor 1 
and 2, the first model which included age (centered on age 18), sex, BDl-II C/A, BDI-II S, BAI, 
and antidepressant use were used as predictors of driving errors. Contrary to our prediction, the 
first model was not statistically significant suggesting that depressive and anxious symptoms, 
and antidepressant medication use was not related to self-reported driving errors or emotional 
violations. A second model was run excluding the BAI as it highly comorbid with the BDI-II 
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(Beck, Steer, & Brown, 1996). This model also included three interactions such as the interaction 
between sex and the BDI-II CA, sex and the BDI-II S, and sex by antidepressant use. This model 
also did not reveal statistically significant results. These findings replicate previous studies. For 
example, Hindmarch (1995) conducted a literature review and reported that SSRIs and TCAs 
were not associated with an increased risk of a crash.. In addition, Iwamoto et al. (2008) 
examined the acute effects of paroxetine, an SSRI, in healthy Japanese males. Results suggested 
no significant differences in standard deviation of lane position (M= 38.9 cm; SD = 9.00 cm) 
compared to controls (M = 37.2 cm; SD = 7.7 cm). 
Our findings contrast with Bulmash et al (2006) who examined driving performance of 
participants (N = 18) with a diagnosis of MDD. These researchers found that participants with 
MDD crashed significantly more frequently compared to controls. Bulmash et al used a driving 
simulator to measure crash rates. The difference in these findings may be attributable to the 
population used. Bulmash et al. used a clinical population and in the present study the majority 
of participants were university students who fell in the minimal range on depressive symptoms. 
Another explanation for insignificant findings is that women report being more compliant with 
traffic regulations and obeying speed limits compared to men (Bergdahl, 2005); the majority of 
our sample was composed of women (79.1%) and therefore there may be less variability in DBQ 
scores. 
Factor 3 is also composed of 5-items that represent absent-mindedness which is 
considered being forgetful or having a low-grade attention. Attention is an important factor when 
driving an automobile. For instance, Weafer, Camarillo, Fillmore, Milich, and Marczinski (2008) 
conducted an experiment to investigate whether symptoms of attention-deficit hyperactivity 
disorder (ADHD) interfere with driving performance. One feature of ADHD is a persistent 
DEPRESSION, ANTIDEPRESSANTS, AND DRIVING 137 
pattern of inattention including failing to pay attention to details or making careless mistakes 
(APA, 2013). Weafer et al. found that individuals with a DSM-IV-TR diagnosis of ADHD 
displayed significantly greater SDLP (M= 1.6; SD = 0.7) compared to controls (M= 1.3; SD = 
0.4;p<.01). 
Both model 1 and model 2 in our study demonstrated overall statistically significant 
results when examining Factor 3. Age and the cognitive and affective impairments on the BDI-II 
emerged as significantly related to self-reported absent-mindedness on the road. More 
specifically, increasing age and increasing cognitive/affective impairments were significantly 
associated with an increase in absent-minded driving behaviour across both models. This finding 
makes logical sense. The cognitive/affective impairments measured by the BDI-II, which 
includes cognitive/affective and somatic impairments measured are also found in older 
individuals. A key feature of MCI and Alzheimer’s disease is a decline in memory and learning 
(APA, 2013). Carvalho, Tan, Springate, and Davis (2013) factor analyzed the BDI-II with a 
sample of older individuals (M= 74 years) with an MCI or Alzheimer’s disease and found that 
the cognitive/affective symptoms of depression accounted for 36% of the variance providing 
support for cognitive/affective impairments among older individuals. Although our sample was 
much younger (M= 21.9; SD = 3.9), our results support the finding that increasing age and 
cognitive/affective impairments is associated with driving errors due to absent-mindedness and 
forgetfulness. No other variables were significant in this model. Furthermore, the two regression 
models for the sum of the four factors did not display significant results. Factor 4, or “reckless 
violations”, are disrespectful in nature and therefore were not examined in relation to the 
dependent variables as there is no theoretical basis for mood and recklessness. 
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Overall, the results of hypothesis two suggest that only cognitive/affective mood 
symptoms and age are associated with driving impairments due to absent-mindedness. 
Medication use, anxiety symptoms, sex, and somatic mood symptoms were not related to 
driving errors, emotional violations, or absent-mindedness. Previous research examining mood, 
medications, and driving performance is limited and has revealed mixed and inconsistent 
findings (see Barbone et al., 1998; Leveille et al., 1994; Wingen et al., 2005). Our findings 
support some previous research. For example, Hindmarch (1995) conducted a literature review 
and found that SSRJs were not associated with a significant increase in accidents. In addition, 
Barbone et al. (1998) also found that antidepressant use was not associated with increased risk of 
a traffic crash using police records. Similarly, Leung, Deane, Taylor, and Bliokas (2009) 
examined the effects of anxiety on driving performance. Regression analyses demonstrated that 
anxiety symptoms were not significantly related to driving outcomes on an on-road test {fi - -0.3, 
p = .07). Taken together, our overall findings for hypothesis 2 suggest that mood impairments 
and age are significantly related to self-reported driving impairments due to absent-mindedness. 
Hypothesis 3 and 4. We expected to observe that higher levels of antidepressant 
medication use and/or depressive symptoms would also predict higher impairments on 
measures of attention (Centre for Research on Safe Driving Attention Network Test [CRSD- 
ANTJ), executive functioning (Trail Making Test [TMT]), visual perceptual ability (Motor- 
Free Visual Perception Test: Third edition [MVPT-3]), and visual information processing 
(Useful Field of View [UFOVJf We also expected to observe that higher levels of 
antidepressant medication use and/or depressive symptoms would predict poorer driving 
performance on the driving simulator. 
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Depressive symptoms can interfere with attentional processes (Egeland et al., 2003; 
Ravnkilde et al., 2002). Contrary to our hypothesis, our regression models as whole showed that 
antidepressant medications and depressive symptoms were not significantly related to 
disturbances in attentional processes. However, a negative relationship was observed between 
diagnostic depressive symptoms on the PHQ-9 and the CRSD-ANT alerting score {B = -2.48, p < 
.05), which is a state of achieving and maintaining attentiveness (Posner, 1980). This finding 
suggests that higher depressive scores are significantly related to poorer alerting performance. In 
contrast, Han et al. (2012) compared Attention Network Test orienting, alerting, and conflict 
scores across adolescents diagnosed with Major Depressive Disorder (MDD; w = 31) and healthy 
controls (« = 30). No significant differences between groups were found for ANT alerting scores 
(F[\, 58] = 0.01;p = .97) or orienting scores (F[\, 58] = 0.8;p = .36). However, Han et al. did 
find a significant difference between conflict response times between adolescents with MDD (M 
= 118.6; SD = 69 J) compared to controls (M= 92.6; SD = 22.8). These findings suggest that 
adolescents with MDD have poorer conflict efficiency, or take longer to detect and resolve any 
conflict in mental operations on the ANT conflict task (Mahoney, Verghese, Goldin, Lipton, & 
Holtzer, 2010). Taken together, there is evidence to suggest that depressive symptoms may 
interfere with attentional processes, which can be considered essential for operating a motor 
vehicle (Tanida & Poeppel, 2006). 
The TMT measures cognitive performance by measuring divided attention, cognitive 
flexibility, sequencing, visual search, psychomotor speed, and conceptual tracking (Mitrushina, 
Boone, & D’Elia, 1999). The UFOV also measures divided attention but in a computerized 
format. Findings in our study suggest that depressive symptoms were not associated with 
significant impairments in performance on the TMT or on the UFOV. These findings are 
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consistent with a study conducted by Hetland et al. (2014), who examined participants taking 
“potentially driver impairing (PDI)” medications, including antidepressant medications, and 
scores on the TMT and UFOV. No significant differences on the TMT were found when 
comparing the whole sample (N= 225; M= 61.7s), participants taking one or more PDI 
medications (n = 155; M= 60.0s), and participants taking no medications (n = 70; M= 65.4s). 
Likewise, no significant differences were demonstrated on the UFOV when examining the whole 
sample (N = 225; M= 270.4s), participants taking one or more PDI medications (« = 155; 
261.3s), and participants taking no medications (n = 70; M= 293.5s). A large portion (39.6%) of 
this sample also met diagnostic criteria for MDD. These findings suggest that mood does not 
significantly impair performance on tasks that demand divided attention and psychomotor speed. 
Our study also examined the influence of mood on a visual perceptual task that does not 
involve psychomotor abilities. Cognitive/affective impairments on the BDI-II were significantly 
correlated with better visual perceptual abilities on the MVPT-3. Higher scores on the MVPT-3 
reflect fewer deficits in visual perceptual abilities. This finding may be explained by “depressive 
realism” (DM), or the depressed individuals process information differently (more accurately) 
than non-depressed individuals (Dykman, Abramson, Alloy, Hartlage, 1989). Moreover, the DM 
hypothesis postulates that depressed individuals can make realistic inferences while non- 
depressed individuals are biased towards optimism which serves to provide them with an illusion 
of control (Moore & Fresco, 2012). Therefore, it is possible that individuals with higher 
cognitive/affective depression scores have more accurate visual perceptual abilities. Kombrot, 
Msetfi, and Grimwood (2013) investigated depressive realism (measured using the BDI-I) and 
the judgement of time perception and psychophysical functions. Participants were asked to 
estimate the length of a tone in seconds while also remembering a number. Participants who 
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scored high on the BDI-I demonstrated more accurate judgements of time perception compared 
to non-depressed participants {p < .05). Moore and Fresco (2012) also conducted a meta-analysis 
of depressive realism literature. Results of over 75 studies indicate that depressed individuals 
exhibit slightly less perceptual/attentional bias compared to non-depressed individuals (Cohen’s 
d = -.07; SD = .46). In contrast, non-depressed individuals demonstrated an optimism bias 
(Cohen’s d = .29; SD = 2.53) such that these individuals tend to believe they have more control 
over an outcome than depressed individuals. Although it is possible that our finding of 
cognitive/affective impairments being associated with better visual perceptual abilities is 
spurious ip = .05), our findings may also lend some support to the hypothesis that greater 
cognitive/affect impairments that contribute to depression, are associated with greater visual- 
perceptual abilities. 
To the best of our knowledge, only one study to date has examined the effects of 
depressive symptoms alone on driving performance. Bulmash et al. (2006) examined driving 
simulator performance in participants who met the DSM-IV-TR diagnostic criteria for MDD and 
who were not taking antidepressant medications. A diagnosis of MDD was determined by staff 
psychiatrists at an outpatient clinic. Severity was assessed using the BDI-II (Af = 27.4; SD = 
11.5). Our study also examined the relationship between depressive symptoms and driving 
performance on the driving simulator in participants who were not taking antidepressant 
medications. Bulmash et al. (2006) found that participants with MDD (« = 18) demonstrated a 
significant increase in crash rates (T|^ = 0.10) and significantly slower reaction times (tj^ = 0.08) 
compared to healthy controls. However, our findings contrast those found by Bulmash et al. For 
example, our findings suggest that depressive symptoms were not associated with impairments in 
driving function on the total score on the Manitoba Road Test, which is a sum score of errors in 
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starting, stopping, signalling, oncoming traffic, passing, intersections, speed, turning, and 
inattention. However, participants in the present study did not meet diagnostic criteria for MDD 
(scores on the PHQ-9 were low; M= 4.2; = 4.1) and participants in Bulmash et al.’s study 
met diagnostic criteria. Moreover, consistent with our study, Bulmash et al. found no significant 
relationship between BDI-II scores and steering response time or crashes on the driving 
simulator suggesting that depressive symptoms were not significantly associated with steering 
impairments or crashes. Overall, these findings suggest that a diagnosis of MDD, or severe 
depressive symptoms, may impair driving performance. However, it is important to consider that 
Bulmash et al. had a veiy small sample size {n= 18) suggesting that the findings may be 
confounded and not generalizable to the population. Given that our sample was composed of 
individuals who did not meet diagnostic criteria for MDD and/or reported mild depressive 
symptoms, there is a risk of committing a type-II error. More specifically, there is a risk of 
failing to reject the null hypothesis when it is true due to an underrepresentation of individuals 
with MDD in our sample. 
Limitations and Future Directions 
There are a number of limitations and suggestions for future research that should be 
considered. Firstly, participants were recruited through convenience sampling from 
undergraduate courses at Lakehead University and from community organizations. Convenience 
sampling may reflect a self-selection bias and may not represent the general population and thus 
may not be generalizable. More specifically, our laboratory sample in particular may have 
differed from those who chose not to participate. It was difficult to recruit individuals who were 
experiencing significant depressive symptoms and/or taking antidepressant medications to 
complete the laboratory portion of our study. Hartlage, Alloy, V^quez, and Dykman (1993) 
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hypothesized a “cognitive effort hypothesis” which proposes that the cognitive deficits 
associated with MDD are directly related to the difficulty of the task. Therefore, highly 
demanding tasks are likely to have a detrimental impact on depressed individuals and thus may 
cause depressed individuals to avoid these tasks. This theory may provide an explanation as to 
why it was difficult to recruit participants who were experiencing significant depressive 
symptoms and/or taking antidepressant medications. We did, however, assess effort using the 
WAIS-IV digit span subtest with participants who completed the laboratory portion of this study. 
Based on reliable digit span-revised scores, only no participants scored in a range that is 
indicative of sub-optimal effort. Therefore, although there is evidence that the participants who 
participated in the laboratory session were motivated to exert effort during participation, it is 
possible that a selection bias may have impacted our results. Future studies should aim to recruit 
participants with MDD and/or participants who are taking antidepressant medications to 
participate in laboratory sessions using a driving simulator. This is especially important given 
that most of the current research has utilised healthy controls rather than clinical populations to 
investigate the influence of MDD and antidepressant medications on driving performance 
(Rapoport & Banina, 2007). One way to maximize the likelihood of participation may be to 
reduce the amount of time a participant spends in the laboratory. A 2-hour session may have 
been perceived as too long and cognitively demanding. Taken together, future studies should be 
sensitive to self-selection bias and design experiments that are shorter in duration. 
An additional factor that may have influenced the generalizability of our findings was 
that participants were recruited from a northern community (Thunder Bay, ON.). This suggests 
that participants in the present study may not have had as much exposure to complex driving 
situations (e.g., traffic circles, complex intersections). This may have reduced the variability of 
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self-reported unsafe driving behaviours on the DBQ. Additionally, the online portion of this 
study was based solely on self-report measures, which may not translate to actual performance. 
“People’s behaviour does not always conform to what they say they would do, so survey 
research will never replace direct observation” (Shaughnessy, Zechmeister, & Zechmeister, 
2006; p. 188). For example, our study found no significant relationship between both versions of 
the DBQ and the simulated driving scores (rs = .03 to .26) suggesting that self-reported driving 
behaviours are not related to actual driving performance. Furthermore, self-reports such as the 
DBQ rely on accurate and reliable responses including recalling information on the DBQ 
pertaining to instances when an individual was forgetful (e.g., forgetting where care was left) 
which seems counterintuitive as it requires participants to recall information that was previously 
forgotten (Lajunen & Summala, 2003). In addition, previous research has documented that 
driver’s tend to fall into the illusory superiority phenomenon wherein they tend to believe that 
they are better than average at the task of driving (Riendeau & Patterson, 2012; Freund, 
Colgrove, Burke, & McLeod, 2005; Svenson, 1981). Therefore, caution should be taken when 
interpreting results from self-report measures. Lastly, we included multiple comparisons in our 
regression analyses and this may have confounded the results. 
One strength of the present study was that we did not solely rely on self-report data. Our 
study included a laboratory portion, which included data from neuropsychological data including 
the CRSD-ANT, UFOV, and MVPT and driving data from a driving simulator. Driving 
simulators have demonstrated validity and are a safe tool for measuring driving performance 
(Bedard et al., 2010; Lee, Cameron, & Lee, 2003). In addition, to the best of our knowledge this 
was the first study to validate the DBQ on a younger Canadian sample using a driving simulator. 
Another strength of this study was that we followed best practices for EFA analyses. For 
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example, Streiner (1994) argues that “there should be an absolute minimum of five subjects per 
variable, with the proviso that there are at least 100 subjects.” (p.l40) suggesting that our overall 
sample size met the minimum standard (n = 266). In addition, Streiner reports that eigenvalues 
must be reported (see Table 13 for eigenvalues) and the sum of the eigenvalues should account 
for at least 50% of the variance. In our study, the eigenvalues for the whole sample met this 
criteria (accounted for a total of 49.9%) and for participants aged 18-35 (« = 233; accounted for a 
total of 43.1%) approached the cut-off for this criteria. Additional best practice criteria that our 
study followed includes: reporting how many factors were retained, specifying factor rotation, 
and including a minimum of 3 variables per factor. 
Overall, future studies could examine the influence of mood and antidepressant 
medications on driving performance with a clinical population using a larger sample size to 
increase power, reduce the risk of committing type I and II errors, and generate more 
generalizable results. The present study also only examined individuals aged 18 to 35 and was 
unable to examine the influence of antidepressant medications due to difficulty with recruitment. 
Future studies could examine older participants and compare the groups to investigate any 
differences in age groups, depressive symptoms, and medication use on driving performance. 
Given that age is strongly related to higher crash rates compared to other age cohorts (Owsley, 
2002), and therefore can be considered a confounding variable, it will be important for future 
studies to control for age and/or compare age cohorts. 
At present, the literature on the influence of mood and medications on driving 
performance continues to be mixed and sparse. However, this study adds to the literature 
because, to the best of our knowledge, this is the first study to examine self-report, 
neuropsychological, and behavioural measures, including actual driving performance in a 
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younger Canadian sample. Overall the main findings of our study were that cognitive affective 
impairments of depression (BDI-II CA) were associated with impairment in both self-report and 
neuropsychological measures. For example, BDI-CA impairments were positively associated 
with self-reported absent-mindedness on the road {B = A2,p< .05) and the CRSD-ANT alerting 
score, which requires a reflexive component and indicates whether an individual can maintain 
attention (-B = 3.45,/? < .05). This lends some support for depressive symptoms interfering with 
attentional processes on the road. The magnitude of these associations may have been stronger if 
our sample consisted of more individuals with severe depressive symptoms. Furthermore, in 
contrast to these findings, the relationship between the BDI-II CA and MVPT-3 {B = 2.02, p = 
.05) reflects fewer deficits in visual perceptual abilities. However, it is important to note that this 
finding may be spurious as/? = .05. The overall patterns of self-report data, neuropsychological 
data, and behavioural data suggest that although there is some consistency between self-report 
measures and neuropsychological data (BDI-II CA; DBQ; CRSD-ANT), this does not 
necessarily mean these impairments in attention translate into actual driving impairments on the 
simulator. Further investigation is needed to provide more conclusive findings. Future studies 
could conduct a similar study using on-road performance as the behavioural measure of driving 
performance. Future research is essential on this topic specifically comparing clinically 
depressed Canadian populations with individuals taking antidepressant medications, healthy 
controls, and across age cohorts. 
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Appendix A 
Demographic Questionnaire 
1. Name  
2. Date of birth (dd/mm/yyyy) ! ! 
3. Sex 
[ ] Male [ ] Female 
4. Mailing address (including postal code) 
5. Phone number: ( )  
6. Email address (if applicable)  
7. How old were you when you obtained your driver’s license? 
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Appendix B 
No. Driving Behaviour Questionnaire 
Please indicate, on average, how frequently you engage in the following behaviours using 
the scale below: 
0 = never 1 = hardly ever 2 = occasionally 3 = quite often 
4 = frequently 5 = very frequently 
Check your speedometer and discover that you are 
unknowingly traveling faster than the legal limit. 
0 1 2 3 4 5 
Lock yourself out of your car with the keys still 
inside. 
2 3 4 5 
Become impatient with a slow driver in the outer lane 
and overtake on the inside. 
2 3 4 5 
Drive as fast along country roads at night with 
headlights on low as on high beam. 
2 3 4 5 
Attempt to drive away without first having switched 
on the ignition. 
2 3 4 5 
Drive especially close or ‘flash’ the car in front as a 
signal to drive faster or get out of your way. 
2 3 4 5 
Forget where you left your car in a multi-level car 
park. 
2 3 4 5 
Distracted or preoccupied, realize belatedly that the 
vehicle ahead has slowed, and have to slam on the 
brakes to avoid a collision. 
2 3 4 5 
Intend to switch on the windshield wipers, but switch 
on the lights instead, or vice versa. 
2 3 4 5 
10 Turn left on to a main road into the path of an 
oncoming vehicle that you hadn’t seen or who’s speed 
you had misjudged. 
2 3 4 5 
11 Misjudge the gap between parked cars and nearly (or 
actually) hit the adjacent vehicle. 
2 3 4 5 
12 “Wake up” to realize that you have no clear 
recollection of the road along which you have just 
traveled. 
2 3 4 5 
13 Miss your exit on a motorway and have to make a 
lengthy detour. 
2 3 4 5 
14 Forget which gear you are currently in and have to 
check with your hand. 
2 3 4 5 
15 Stuck behind a slow moving vehicle on a two-lane 
highway, you are driven by frustration to try to over- 
take in risky circumstances. 
2 3 4 5 
16 Intending to drive to destination ‘A’, you “wake up” 4 5 
DEPRESSION, ANTIDEPRESSANTS, AND DRIVING 176 
to find yourself on route to ‘B’, where the latter is 
more the usual journey. 
17 Take a chance and cross on lights that have turned red. 2 3 4 5 
18 Angered by another driver’s behaviour, you give 
chase with the intention of giving him/her a piece of 
your mind. 
2 3 4 5 
19 Try to overtake without first checking in your mirror, 
and then get honked at by the car behind you which 
has already begun its overtaking manoeuvre. 
2 3 4 5 
20 Deliberately disregard the speed limits late at night or 
very early in the morning. 
2 3 4 5 
21 Forget that your licence/plates have expired and 
discover that you are driving illegally. 
2 3 4 5 
22 Lost in thought, you forget that your lights are on high 
beam until ‘flashed’ by another vehicle. 
2 3 4 5 
23 On turning right, nearly hit a cyclist who has come up 
on your inside. 
2 3 4 5 
24 In a line of vehicles turning right on to a main road, 
pay such close attention to the traffic approaching 
from the left that you nearly hit the car in front. 
2 3 4 5 
25 Drive back from a party, restaurant, or pub, even 
though you realize that you may be over the legal 
blood-alcohol limit. 
2 3 4 5 
26 Have an aversion to a particular class of road user, and 
indicate your hostility by whatever means you can. 
2 3 4 5 
27 Lost in thought or distracted, you fail to notice 
someone waiting at a crosswalk or a pedestrian 
crosswalk light that has just turned red. 
2 3 4 5 
28 Park in a no parking area and risk a fine. 2 3 4 5 
29 Misjudge the speed of an oncoming vehicle when 
overtaking. 
2 3 4 5 
30 Hit something when backing up that you had not 
previously seen. 
2 3 4 5 
31 Fail to notice someone stepping out from behind a bus 
or parked vehicle until it is nearly too late. 
2 3 4 5 
32 Plan your route badly, so that you meet traffic 
congestion you could have avoided. 
2 3 4 5 
33 Overtake a single line of stationary or slow-moving 
vehicles, only to discover that they were lining up to 
get through a one-lane gap or roadwork lights. 
2 3 4 5 
34 Overtake a slow-moving vehicle on the inside lane or 
hard shoulder of a motorway. 
2 3 4 5 
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35 Cut the comer on a left-hand turn and have to swerve 
violently to avoid an oncoming vehicle. 
2 3 4 5 
36 Get into the wrong lane to make a left or right hand 
turn at an intersection. 
2 3 4 5 
37 Fail to read the signs correctly and exit from a 
highway on the wrong road. 
2 3 4 5 
38 Fail to give right of way when a bus is signaling its 
intention to pull out. 
2 3 4 5 
39 Ignore yield signs and narrowly avoid colliding with 
traffic that has the right of way. 
2 3 4 5 
40 Fail to check your mirror before pulling out, changing 
lanes, turning etc. 
2 3 4 5 
41 Attempt to overtake a vehicle that you hadn’t noticed 
was signaling its intention to turn left. 
2 3 4 5 
42 Deliberately drive the wrong way down a deserted 
one-way street 
2 3 4 5 
43 Disregard red lights when driving late at night along 
empty roads. 
2 3 4 5 
44 Drive with only ‘half-an-eye’ on the road while 
looking at a roadmap, dialing/text messaging on a cell 
phone, changing a cassette/CD or radio channel. 
2 3 4 5 
45 Fail to notice pedestrians crossing when turning into a 
side-street from a main road. 
2 3 4 5 
46 Get involved in unofficial ‘races’ with other drivers. 2 3 4 5 
47 ‘Race’ oncoming vehicles for a one-car gap on a 
narrow or obstructed road. 
4 5 
48 Brake too quickly on a slippery road and/or steer the 
wrong way in a skid. 
2 3 4 5 
49 Misjudge your crossing interval when turning left and 
narrowly miss colliding with an oncoming vehicle. 
2 3 4 5 
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Appendix C 
Driving History/Habits Questionnaire 
1. Date (dd/mm/yyyy) ! !  
2. Approximately how many kilometres (miles) do you drive per week? 
[ ] 0-20 km (0-12 m) [ ] 51-100 km (32-62 m) 
[ ] 21-50 km (13-31 m) [ ] over 100 km (> 62 m) 
3. How long ago was your last car collision involving a person, car, or fixed object? 
[ ] Less than 1 year [ ] 4-5 years 
[ ] 1-2 years [ ] 5-10 years 
[ ] 2-3 years [ ] More than 10 years 
[ ] 3-4 years [ ] Never had an accident 
4. When driving, how many collisions (involving a person, car, or fixed object) have you been 
involved in? {Do not include cases where you were a passenger)  
For how many of these was reporting to the police deemed unnecessary?  
5. For what purposes do you drive in a typical week? (Check all that apply to you) 
How many times per week? 
[ ] Groceries  
[ ] Other shopping (e.g., drug store, clothes shopping)   
[ ] Health-related appointments (e.g., doctor, dentist)  
[ ] Social events (e.g., recreation centres, friends)   
[ ] Worship (e.g., church, synagogue, etc.) 
[ ] Hobby-related (e.g., attend classes) 
[ ] Work, school, or volunteer activities 
[ ] Family events 
[ ] Other, please specify  
6. Which driving situation(s) do you find stressful, 
(Check all that apply to you) 
[ ] Turning left at intersections 
[ ] Driving at night 
[ ] Backing up 
[ ] Parallel parking 
[ ] Driving in unfamiliar areas 
[ ] Driving with passengers in the car 
[ ] Driving alone 
uncomfortable, or avoid when possible? 
[ ] Navigating parking lots 
[ ] Changing lanes 
[ ] Maintaining the speed limit 
[ ] Driving in bad weather 
[ ] Driving in heavy traffic 
[ ] Other  
[ ] None of the above 
7. Some people restrict their driving to certain situations. Do you restrict your driving to: 
(Check all that apply to you) 
[ ] Daytime [ ] Local routes 
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[ ] When accompanied by a passenger 
[ ] Outside of rush hour 
[ ] Fair weather 
[ ] Other  
[ ] None of the above 
8. With regard to the speed limit on local streets (posted speed limit of 50 km/hr), do you 
typically drive: 
[ ] 35 km/hr or less 
[ ] 36-45 km/hr 
[ ] 46-55 km/hr 
[ ] 56-65 km/hr 
[ ] 66 km/hr or more 
9. With regard to the speed limit on major highways (posted speed limit of 90 km/hr), do you 
typically drive: 
[ ] 85 km/hr or less 
[ ] 86-95 km/hr 
[ ] 96-105 km/hr 
[ ] 106-115 km/hr 
[ ] 116 km/hr or more 
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Appendix D 
Medication History Questionnaire 
1. Date (dd/mm/yyyy) ! !_ 
2. Are you currently taking medications? 
□ Yes □ No 
If yes. 
Please list all your current medications; write the specific name(s) as printed on the medication 
label(s) and then indicate the dose. 










3. Are you currently seeing a therapist or seeking treatment for depression and/or anxiety? 
□ Yes □ No 
4. Have you seen a therapist in the past for treatment for depression and/or anxiety? 
□ Yes □ No 
a. If yes, please indicate when you saw a therapist and for how long you saw a 
therapist 
5. Have you ever had a serious head injury? 
□ Yes □ No 
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b. If yes, please indicate when you experienced a serious head injury 
6.D0 you have any of the below conditions? 
Yes 
Diabetes or high blood sugar Qi 
Heart disease Qi 
Stroke Qi 
Seizures or epilepsy Qi 
Parkinson’s disease □ 1 
Sleep apnea or sleeping sickness □ i 
Narcolepsy Gi 
Dementia (e.g., Alzheimer disease) Gi 
Physical Frailty (reduced flexibility or reduced muscle strength) Gi 
Poor hearing Gi 
Poor vision Gi 
Arthritis Gi 
Broken bones Gi 
Sudden lapses in consciousness (Syncope) Gi 
Other Gi 
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Appendix E 
Driving Simulator Evaluation Form 
Lakehead University 
I. STARTING 
A. Fails to check traffic  
B. Fails to signal  
C. Fast or uneven get-away. 
D. Rolls when on grade  
E. Starts before light green.. 
Deduct 
.... 5.... 






A. Stops for no reason  
B. Stops too suddenly  
C. Over-running crosswalk. 
D. Not at safe place  








m. SIGNAL VIOLATIONS 
Deduct 
A. Thru on red 5.... 
B. Thru on red (enters amber).. .5  
C. Thru on red (right turn) 5  
“ Stop Sign “ 
D. Does not stop 5.... 
E. Leave when not safe 5  
Deduction 
IV. VEHICLES MOVING ON ROADWAY 
Deduct 
A. Straddles traffic lane 5  
B. Follows too closely  5  
C. Fails to check 
changing lanes 5  
D. Fails to signal  5  
E. Cuts off vehicle 10  
F. Drives wrong side of street... 5  
G. Wanders 5  
H. Crosses solid line 5  
I. Uncertain gear shifting 5  




A. Too close to pedestrians 
or vehicles 5.... 
B. Passes when unlawful 
Or unsafe 10  
C. Speeds up when 
being passed 10  
Deduction 
VI. UNCONTROLLED INTERSECTIONS/RAILWAY 
CROSSINGSA^IELD SIGNS/PEDESTRIAN 
CORRIDORS OR CROSSWALKS 
Deduct Deduction 
A. Fails to slow down 
or check 5  
B. Fails to yield 10  
VII.SPEED 
Deduct Deduction 
A. Exceeds stated 
speed limit 10  
B. Too fast for conditions 5  
C. Slows unnecessarily before 
or after lane change 5  
D. Slows thru intersection 5  
E. Hinder or drives too slowly 5  
F. Drives at uneven speed 5  
VIII.TURNING 
A. Improper signal  
B. Improper approach. 
C. Improper during  
D. Improper after  
E. Improper speed  
F. Shies away  
G. Strikes/over curbs... 
H. Fails to yield  
Fails to establish. 





 5  
 5  
 5  








A. Leaves signal on 5  
B. Signals through intersection 5  
C. Hesitant 5  
D. Fails to yield 
emergency vehicle 5  
PARTICIPANT #: DATE: 
ROAD TEST RESULTS: 
PASS FAIL 
GRAND TOTAL 
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Appendix F 
Participant Information Sheet A 
The Influence of Mood and Medications on Driving Performance 
Dear Potential Participant: 
Thank you for taking part in this research study investigating the role of mood and medications 
on driving performance. 
During this study you will be asked to complete a series of online questionnaires. This study will 
take approximately 0.5 hours to complete. Following completion of this study, a research 
assistant may contact you to invite you to a follow-up laboratory portion of this study, if you 
agree to be contacted further. 
This research project is being conducted under the supervision of Dr. Michel Bedard and Dr. 
Dwight Mazmanian. Only Dr. Bedard and Dr. Mazmanian, a research assistant, and Loretta 
Patterson will have access to the information you provide. Your information will be assigned a 
unique subject number to ensure anonymity and confidentiality. The information will be securely 
stored in the Centre for Research on Safe Driving (CRSD) at Lakehead University for at least 
five years. In addition, your identifying information will be kept completely confidential 
throughout reports of results and publications. This study has received support from St. Joseph’s 
Care Group Award in Applied Health Research and the Canadian Institutes of Health Research. 
Participation in this research study is completely voluntary and you may decline to answer any 
question or refuse to participate in any part of this study. If for any reason you wish to withdraw 
from the study you may do so at any time without penalty. The physical risk associated with this 
study will be the same as that of working with a personal computer for up to 30 minutes. In terms 
of psychological risk, there is a chance that you may experience some psychological discomfort 
subsequent to completing two questionnaires that ask about symptoms of depression and anxiety. 
Given that this is a risk, we will provide you with a list of psychological services. You will 
receive one Psychology 1100 bonus point for your participation if you are enrolled in this course. 
This study has been approved by the Lakehead University Research Ethics Board, who may be 
contacted at 1-807-343-8934. If you have questions or concerns regarding the ethics of the 
project, please contact the Research Ethics Officer at 1-807-343-8283. 
A report of findings will be available to those interested upon request. If you require additional 
information please do not hesitate to contact one of the researchers. 
Thank you. 
Loretta Patterson, M.A. 
PhD Student, Clinical Psychology 
Michel Bedard, PhD 
Canada Research Chair in Aging and Health 
DEPRESSION, ANTIDEPRESSANTS, AND DRIVING 184 
Lakehead University 
Phone: (807) 766-7256 
Email: lblanche@lakeheadu.ca 
Director, Centre for Research on Safe Driving 
Lakehead University 
Phone: (807) 343-8630 
Email: mbedard@lakeheadu.ca 
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Appendix G 
CONSENT FORM A 
By providing my name, student number, and E-mail, and checking the box below, I indicate that 
I have read the previous “Participant Information Sheet” and that I agree to participate in this 
study which is conducted by Loretta Patterson in the Department of Psychology for her PhD 
dissertation under the supervision of Dr. Michel Bedard and Dr. Dwight Mazmanian. I 
understand that any questions that I might have about my participation can be answered by 
Loretta Patterson and/or Drs. Bedard and Mazmanian. In providing my identifying information 
below, I understand and agree to the following: 
1.1 understand the information on the “Participant Information Sheet”. 
2.1 agree to participate in this study. 
3.1 fully understand what I will be required to do as a participant in this study. 
4.1 am a volunteer and can withdraw at any time from this study without penalty or 
consequence. 
5.1 may choose not to answer any question asked in the questionnaires without penalty or 
consequence. 
6. My data will be confidential and stored in the Centre for Research on Safe Driving (CRSD) 
for a period of at least five years. 
7. My information will remain anonymous should any publications or public presentations come 
out of this study. 
8.1 may receive a summary of this research study upon completion of this study. 
9.1 give my permission to be contacted by telephone and/or E-mail for the purpose of 
participation in this study. 
I agree to participate in the study examining mood, medications, and driving. 
Full Name {please print) Date 
 Please check this box to consent Q 
E-mail 
Student Number Phone 
Name of Psychology 1100 Professor 
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I agree to be contacted regarding future studies being conducted by researchers in the Centre for 
Research on Safe Driving (CRSD). 
Signature of Participant Date 
Email Address:  
Phone Number: ( ) 
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Appendix H 
Participant Information Sheet B 
The Influence of Mood and Medications on Driving Performance 
Dear Potential Participant: 
Thank you for taking part in this research study investigating the influence of mood and 
medications on driving performance. 
During this study you will be asked to complete two computerized tasks (one to assess 
processing speed and one to measure attention), a series of questionnaires designed to measure 
depression, driving habits, cognitive and psychomotor functioning, a structured interview with 
the experimenter that assesses your mood and substance use, and a 40 minute simulated drive. If 
you wear glasses, we ask that you bring them with you to the laboratory. In addition, if you are 
taking any medications, we ask that you bring your prescription bottles with you to the 
laboratory session. This study will take approximately 2 hours to complete. 
This research project is being conducted under the supervision of Dr. Michel Bedard and Dr. 
Dwight Mazmanian. Only Dr. Bedard and Dr. Mazmanian, a research assistant, and Loretta 
Patterson will have access to the information you provide. Your information will be assigned a 
unique subject number to ensure anonymity and confidentiality. The information will be securely 
stored in the Centre for Research on Safe Driving (CRSD) at Lakehead University for at least 
five years. In addition, your identifying information will be kept completely confidential in 
reports of results and publications. This study has received support from the St. Joseph’s Care 
Group Award in Applied Health Research and the Canadian Institutes of Health Research. 
Participation in this research study is completely voluntary and you may decline to answer any 
question or refuse to participate in any part of this study. If for any reason you wish to withdraw 
from the study you may do so at any time without penalty. There is a chance that you may 
experience simulator discomfort while on the driving simulator. If this occurs, the simulation can 
be paused or terminated. Other than that, the physical risk will be the same as that of working 
with a personal computer for up to 60 minutes and driving under normal conditions for up to 45 
minutes. Given that this study is investigating mood, a list of local psychological services will be 
provided to you should you want to contact them. In addition, we may provide you with a letter 
recommending that you contact these services. We may also contact you in 3 months to invite 
you to participate in a follow-up portion of this study. You will receive up to four Psychology 
1100 bonus points for your participation. More specifically, you will receive two points for the 
first laboratory portion of this study and two for the 3-month follow-up portion. 
This study has been approved by the Lakehead University Research Ethics Board, who may be 
contacted at 1-807-343-8934. If you have questions or concerns regarding the ethics of the 
project, please contact the Research Ethics Officer at 1-807-343-8283. 
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A report of findings will be available to those interested upon request. If you require additional 
information please do not hesitate to contact one of the researchers. 
Thank you. 
Loretta Patterson, M.A. 
PhD Student, Clinical Psychology 
Lakehead University 
Phone: (807) 766-7256 
Email: lblanche@lakeheadu.ca 
Michel Bedard, PhD 
Canada Research Chair in Aging and Health 
Director, Centre for Research on Safe Driving 
Lakehead University 
Phone: (807) 343-8630 
Email: mbedard@lakeheadu.ca 
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Appendix I 
CONSENT FORM B 
By providing my name, student number, and E-mail, 1 indicate that I have read the previous 
“Participant Information Sheet” and that I agree to participate in this study which is conducted 
by Loretta Patterson in the Department of Psychology for her PhD dissertation under the 
supervision of Dr. Michel Bedard and Dr. Dwight Mazmanian. I understand that any questions 
that I might have about my participation can be answered by Loretta Patterson and/or Drs. 
Bedard and Mazmanian. By providing my identifying information below, 1 understand and agree 
to the following: 
1.1 understand the information on the “Participant Information Sheet”. 
2.1 agree to participate in this study. 
3.1 fully understand what I will be required to do as a participant in this study. 
4.1 am a volunteer and can withdraw at any time from this study without penalty or 
consequence. 
5.1 may choose not to answer any question asked in the questionnaires without penalty or 
consequence. 
6.1 understand that some participants may experience simulator discomfort while on the driving 
simulator, and that the simulation may be paused or terminated should I experience simulation 
discomfort. Other than that, the physical risk will be the same as that of working with a personal 
computer for up to 60 minutes and driving under normal conditions for up to 45 minutes. 
7.1 am aware that I may receive a letter recommending that I seek psychological services. 
8.1 am aware that I will receive a list of psychological services and that these can be used should 
I experience distress during my participation in this study. 
9. My data will be confidential and stored in the Centre for Research on Safe Driving (CRSD) 
for a period of at least five years. 
10. My information will remain anonymous should any publications or public presentations 
come out of this study. 
11.1 may receive a summary of this research study upon completion of this study. 
12.1 give my permission to be contacted by telephone and/or E-mail for the purpose of 
participation in this study. 
I agree to participate in the study examining mood and driving. 
Full Name {please print) Date 
Signature (please sign) E-mail 
Student Number Phone 
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Name of Psychology 1100 Professor 
I agree to be contacted regarding future studies being conducted by researchers in the Centre for 
Research on Safe Driving (CRSD). 
Signature of Participant Date 
Email Address:  
Phone Number: ( ) 
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Appendix J 
Below is a list of agencies that offer mental health services for your information. Thank you 
again for your participation in this study. 
1. Lakehead University Student Health and Counselling Centre (807-343-8361) 
Located across from Security, near the Agora and University Centre Theatre. Personal 
counselling for students covering a wide variety of issues. 
2. Family Services Thunder Bay (807-684-1880) 
A not-for-profit organization providing confidential counselling, advocacy, education, 
and support for individuals and families in Thunder Bay. Counsellors provide 
comprehensive help for a wide variety of issues such as grief and coping, substance use, 
credit and financial problems, anger, anxiety, depression, and past experiences of 
violence. Fees are based upon individual circumstances and no person will be denied 
service due to an inability to pay. 
3. Personal Development Centre (St. Joseph’s Care Group). (807-343-2400) 
An adult out-patient program which offers and innovative, multi-disciplinary approach to 
treating a variety of mental health issues such as anxiety, depression, stress related 
problems, self-esteem issues, and compromised coping strategies. A physician’s referral 
is required for admission to the program. 
4. Thunder Bay Crisis Response Service (807-346-8282) (Toll free 1-888-269-3100) 
This is a community based crisis response support program for individuals experiencing a 
mental health crisis in the Thunder Bay District. 
5. Canadian Mental Health Association (807-345-5564: 200 Van Norman St. Thunder 
Bay, ON. P7A 4B8; http://www.cmha-tb.on.ca) 
CMHA is a Canada-wide organization that promotes mental health of all and supports the 
recovery of people who are experiencing a mental illness. The CMHA has programs that 
assist with employment, interventions for youth, housing, peer support, recreation 
services for individuals with mental illness, and public education for the community. 
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Appendix K 
Participant Recommendation Letter 
Dear Participant, 
We would like to thank-you again for your participation in this study examining mood and 
medications on driving performance. 
As part of this study, the experimenter asked you some questions pertaining to how you have 
been feeling over the past two weeks. Your answers to these questions suggested that you may 
benefit from seeking psychological and medical support. We have provided you with a list of 
psychological services should you wish to contact them. 
You may also contact Loretta Patterson and/or Dr. Bedard with any questions you may have 
regarding seeking psychological support. 
Thank you, 
Loretta Patterson, M.A. 
PhD Student, Clinical Psychology 
Lakehead University 
Phone: (807) 766-7256 
Email: Iblanche@lakeheadu.ca 
Michel Bedard, PhD 
Canada Research Chair in Aging and Health 
Director, Centre for Research on Safe Driving 
Lakehead University 
Phone: (807) 343-8630 
Email: mbedard@lakeheadu.ca 
